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More than 12.7 million Americans are expected to develop Alzheimer’s Disease 
(AD) by 2050. Identified risk factors for AD include advanced age, female sex, family 
history, the presence the Ɛ4 allele of the apolipoprotein E (APOE) gene, and vascular risk 
factors and conditions. Differential effects by sex appear among some of these risk 
factors, however, sex differences have not been well-studied among others. This project 
examined sex differences in the association between family history of AD, direct 
maternal and paternal lineage of AD, parental longevity, and potential modifying effects 
of cardiovascular risk factors and conditions in the risk for AD in a single population. 
This project used extant data from the Cache County Study on Memory in Aging 
(CCSMA) of 5,092 older adults, enriched with data from Medicare claims and death 
certificates through the Utah Population Database. The results showed that having a first-
degree relative with AD was associated with a 58% increase in AD in males, Odds Ratio 
(OR)= 1.58, p= .003, and a 66% increase in risk in females, OR= 1.66, p= <.001. In 




increased risk for AD, OR= 1.56, p=.005, whereas in males there was a trend, where 
having both direct maternal and paternal lineages of AD were associated with a 51.3% 
lower risk of AD, OR=0.487, p = .054. A history of maternal or paternal exceptional 
longevity was not associated with AD risk in females. In contrast, males who were APOE 
Ɛ4 carriers and with a history of exceptional maternal longevity were at 3-fold greater 
risk of AD than those males with neither risk factor, OR= 3.15, p= .020. Interestingly, 
males had 11% reduced risk for AD with a history of both exceptional maternal and 
paternal longevity, OR= 0.894, p=.041. With respect to vascular factors and interactions 
with family history, females with a history of congestive heart failure (CHF) and direct 
paternal lineage of AD were at a 2-fold increased odds of AD, OR= 2.26, p= .013, 
compared to females with neither risk factor. Those with a history of CHF were at an 11-
fold increased risk for AD, OR= 11.15, p=<.001. For males, there were no interactions 
between family history of AD and vascular risk factors and conditions. Amongst both 
females and males, several vascular factors or conditions were associated with increased 
risk of AD, for instance, cerebrovascular accident and CHF for both females and males, 
and hypertension and high cholesterol/triglycerides/atherosclerosis in males only. 
Notably, a history of myocardial infarction in females was associated with lower risk of 
AD. Overall, this study highlights the increased risk of AD among those with a positive 
family history of AD in first-degree relatives, and sex differences in maternal or paternal 
lineage, and vascular risk factors and conditions. Further research is needed to elucidate 
the mechanisms underlying the above associations to develop potential preventive 
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More than 6 million Americans are living with Alzheimer’s Disease (AD) and this 
number is expected to rise and surpass 12.7 million individuals by the year 2050. 
Currently there is no cure for the disease and prior research has focused on prevention by 
identifying risk factors. Known risk factors associated with AD include older age, female 
sex, genetics, family history of AD, genotype of the apolipoprotein E (APOE) gene, and 
vascular risk factors (e.g., cholesterol, hypertension) and conditions or events (e.g., CHF, 
stroke). The effects of many of the above risk factors have differed in men and women, 
but few studies have examined how family history of AD, direct maternal or paternal 
lineage of AD, parental longevity, and cardiovascular risk factors and conditions might 
influence risk for AD differently for men and women. This project analyzed existing data 
from a population-based longitudinal study, the Cache County Study on Memory in 
Aging (CCSMA), that included permanent residents of Cache County, Utah who were 
aged 65 years or older in 1995. The study’s data were enriched through additional data 
obtained for extended family history and Medicare claims and death certificates that were 
made available through data linkage with the Utah Population Database. The original 
study ran from 1995-2007, but with the additional Medicare claims and death certificates, 




this current study was to examine whether the risk for AD differed between men and 
women with regards to family history of AD, maternal and paternal lineage of AD, 
longer-lived parents, and whether vascular health conditions affected these risks.  
Results from this dissertation showed that having a first-degree relative (parents, 
siblings, or offspring) with AD increased the risk for AD in men by 58%, Odds Ratio 
(OR)= 1.58, p= .003, and women by 66%, OR= 1.66, p= <.001. Among women, direct 
maternal but not paternal lineage of AD was associated with a 56% increased risk for 
AD, OR= 1.56, p=.005, whereas in men, history of maternal or paternal lineage of AD 
(above age 87) did not affect their risk of developing AD. Having a longer-lived mother 
or longer-lived father was not associated with AD risk in women. However, men with a 
history of a longer-lived mother and who had an APOE Ɛ4 positive genotype had three 
times the risk of AD, OR= 3.15, p= .020. Men who had both a longer-lived mother and a 
longer-lived father compared to men without had an 11% reduction in risk for AD, OR= 
0.89, p=.041. In relation to cardiovascular conditions and risk in women, those with a 
history of congestive heart failure (CHF) and a direct paternal lineage of AD had double 
the risk of AD compared to those without, though those women with no paternal lineage 
of AD were at an 11 times greater risk, OR= 11.15, p=<0.001. For men there were no 
associations between family history of AD and cardiovascular conditions. Among both 
men and women, several cardiovascular risk factors increased risk for AD. For instance, 
men and women with a history of stroke or CHF had an increased risk for AD. Men with 
a history of hypertension and high cholesterol/triglycerides/atherosclerosis were also at 
increased risk of developing AD. Notably, women with a history of myocardial infarction 




Although this study is observational in nature and thus does not prove a direct 
causal relationship between familial history and AD, it does support previous research 
that found having a first-degree relative with AD regardless of sex increased the risk for 
AD. The study also highlighted the importance of studying risk factors like family 
history, separately for men and women. Thus, women with a maternal history of AD 
were at greater risk than those with a paternal history of AD, but no such association was 
found in men. Men were at slightly reduced risk for AD when having both longer-lived 
parents and there were slight differences by sex in cardiovascular risk factors that 
predicted risk for AD. The different results obtained for men and women have clinical 
implications in monitoring for AD risk in older adults and suggest aggressive treatment 
for vascular risk factors and conditions amongst women in particular, with CHF and 
family history. Further research is needed to understand the underlying mechanisms with 
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Approximately 6.2 million Americans are living with Alzheimer’s Disease (AD) 
and this number is expected to rise to more than 12.7 million individuals by the year 2050 
(Alzheimer’s Association, 2021). Currently, there is no cure for the disease and one 
priority has been on prevention (Alzheimer’s Association, 2021). Identified risk factors 
associated with sporadic, late-onset AD include advanced age (Guerreiro & Bras, 2015), 
female sex (Mielke et al., 2014), family history (Cannon-Albright et al., 2019), carrying 
the apolipoprotein Ɛ4 allele (APOE Ɛ4; Farrer et al., 1997), and vascular risk factors and 
conditions (Barnes & Yaffe, 2011). Among several of these risk factors, there appears to 
be differential effects in males and females.  
Females account for two-thirds of cases of AD in the US (Alzheimer’s 
Association, 2021). Differences in longevity have been used to explain the differing rates 
in males and females; however, some research suggests this does not fully explain the 
disparity (Mielke et al., 2014). The underlying mechanism associated with sex 
differences in AD risk remains unclear. One factor possibly contributing to this disparity 
includes the maternal/paternal transmission of the disease to the offspring (Mosconi et al., 
2007; Mosconi et al., 2010). 
A family history of AD is a risk factor for the disorder. Several studies have found 
that a positive family history is associated with a 4-10 times increased risk of developing 
AD (van Duijn et al., 1991; Fratiglioni et al., 1993). Having at least one first-degree 




affected first-degree relative, the risk further increases approximately 2-fold (van Duijn et 
al., 1991; Fratiglioni et al., 1993). A recent study reported that extended family history 
also was associated with risk of AD, and risk differed by sex of the affected parent 
(Cannon-Albright et al., 2019). Cannon-Albright and colleagues (2019) found that having 
a first-degree relative with AD increased the risk of AD, which exponentially increased 
with each additional first-degree relative affected. In addition, the authors found sex 
differences in the transmission of AD in second-degree relatives, with a greater increase 
in risk found in the maternal familial line (Cannon-Albright et al., 2019). Several other 
studies have also found varying risk associated with maternal and paternal transmission 
of AD, with a stronger association in the maternal transmission (Honea et al., 2012; 
Mosconi et al., 2007; Mosconi et al., 2010). Recent studies have found evidence of 
significant AD biomarkers in those with a maternal family history compared to those 
with a paternal family history or among those without a positive family history. The 
associations in biomarkers included an increased deposition of Pittsburgh B Compound 
(PiB) in the parietal, sensorimotor cortices, and precuneus of the brain (Honea et al., 
2012) and reduced glucose metabolism in the medial-temporal lobe, parietotemporal 
region, posterior cingulate, and frontal cortices (Mosconi et al., 2007). In cerebrospinal 
fluid, reduced beta amyloid and increased tau/amyloid-beta ratio have been reported 
(Honea et al., 2012). However, a large study of 1,220 older adults, found an association 
with paternal but not maternal transmission of AD (Ehrenkrantz et al., 1999). It is unclear 
what factors underlie these discrepant results, although sex of the proband, health-related 




The apolipoprotein E (APOE) gene has been associated with risk for developing 
AD. Several studies have reported varying effects in males and females who carry the 
APOE Ɛ4 allele. Specifically, many have found a greater risk of AD in female APOE Ɛ4 
allele carriers compared to male carriers of the allele (Bretsky et al., 1999; Farrer et al., 
1997). However, males with two APOE Ɛ4 alleles also appear to be at greater risk of AD 
than those males carrying one or no APOE Ɛ4 allele (Payami et al., 1996). This sex 
difference may contribute to the differing rates of AD amongst males and females and 
may contribute to discrepant results in family history studies.  
As noted above, greater longevity is associated with increased AD risk (Guerreiro 
& Bras, 2015). Sex differences also appear in longevity, with females living longer than 
males (Center of Disease Control [CDC], 2017), and thus, this factor may contribute to 
sex differences in AD rates and discrepant family history studies (Passarino et al., 2016). 
Exceptional longevity (generally defined as aging beyond age 85) however, is associated 
with lower risk of AD (Jorm & Jolley, 1998), delayed onset of cognitive decline 
(Andersen et al., 2012), as well as reduced morbidity (Andersen et al., 2012; Westendorp 
et al., 2009). Offspring of exceptionally long-lived parents have shown reduced 
cardiovascular health conditions (Westendorp et al., 2009) as well as reduced risk of 
developing AD (Lipton et al., 2010). Little research has examined how parental longevity 
relates to sex differences in AD risk or differences in maternal or paternal transmission.  
As noted above, exceptional parental longevity is associated with reduced 
morbidity in offspring (Westendorp et al., 2009) and in particular, cardiovascular 
conditions (Westendorp et al., 2009). Cardiovascular risk factors and conditions, which 




hypercholesterolemia, low physical activity, diabetes mellitus, stroke, obesity, and 
metabolic syndrome (de Bruijn & Ikram, 2014). There are sex differences in the type or 
form of cardiovascular disease (CVD) as well. Females appear to have greater risk for 
developing CVD through microvascular disease, whereas males show greater risk with 
obstructive coronary disease (Bairey-Merz et al., 2006). In AD, significant microvascular 
changes have been observed in the brain and these changes have been associated with 
more severe AD symptomology (De la Torre, 2002). In addition, studies have found that 
compared to males, females are at greater risk for complications due to diabetes mellitus 
such as myocardial infarction, depression, and coronary heart disease (Kautzky-Willer et 
al., 2016). These conditions have also been associated with increased risk for AD (Barnes 
& Yaffe, 2011). Taken together, the unique cardiovascular profile in females may put 
them at higher risk for AD compared to males. However, few studies have investigated 
the type of coronary heart disease and risk for AD in either males or females.  
The above literature discusses several modifiable and non-modifiable risk factors 
of AD. Interesting associations with AD are noted for familial history of AD in maternal 
vs. paternal lines, the role of exceptional longevity, the overall lower risk of 
cardiovascular morbidity with exceptional longevity and sex differences in 
cardiovascular disease risk. These studies have been conducted in various samples and 
together identify important risk factors for AD. However, sex differences in the role of 
family history, exceptional longevity and cardiovascular risk factors and conditions have 
not been well studied. This project examined the association between direct maternal and 
paternal lineage of AD and AD risk and examined sex differences in risk in a single 




conditions were examined as potential modifiers of these relationships. This project used 
extant data from the Cache County Study on Memory in Aging (CCSMA), a longitudinal 
population-based study of antecedents of dementia and cognitive decline in a sample of 
5,092 older adults. Linkage of the CCSMA with the Utah Population Database (UPBD) 
allowed for enrichment of the available data by extending data obtained from other 
sources to include extended family history information and through further linkage with 






REVIEW OF THE LITERATURE  
Risk Factors for Alzheimer’s Disease 
It is estimated nearly 12.7 million individuals in the United States will be living 
with Alzheimer’s Disease (AD) by the year 2050 (Alzheimer’s Association, 2021). There 
is no cure for the disease, and efforts have focused on identifying risk factors for primary 
prevention (Alzheimer’s Association, 2021). Several risk factors for AD have been 
identified and include mid-life hypertension, high cholesterol, diabetes mellitus, diet, and 
sleep disturbance (Barnes & Yaffe, 2011). The greatest risk factor appears to be advanced 
age, with those living longer exhibiting greater risk (Alzheimer’s Association, 2021). 
Family history is also a strong predictor of AD, reflecting both genetic transmission as 
well as lifestyle traditions or psychosocial factors "handed down" across generations 
(Cannon-Albright et al., 2019). Sex differences have been reported in AD, with females 
exhibiting greater risk than males (Nebel et al., 2018). However, the underlying 
mechanisms contributing to this disparity (e.g., greater longevity in women, differences 
in hormonal changes in late life, and various lifetime psychosocial factors) remains 
unclear. This project examined select factors that may contribute to sex differences in AD 
risk. 
Alzheimer’s Disease in Females  
AD is more prevalent among females where it accounts for approximately two-
thirds of all cases in the US (Alzheimer’s Association, 2021). Compared to males, 




al., 2018). It is estimated that after the age of 45, the lifetime risk of developing AD in 
females is approximately 20%, compared to approximately 10% in males (Nebel et al., 
2018).  
Many studies have investigated sex differences in the risk for AD in advanced 
age. The Cache County Study on Memory in Aging (CCSMA) found modest differences 
in incidence rates of AD between males and females prior to age 78, after which the 
incidence of AD increased two-fold (with age) in females compared to males. Incidence 
rates for both males and females declined with age in the mid-to-late 90s and beyond 
(Miech et al., 2002). Similarly, Roberts and colleagues (2012) found conversion rates 
from Mild Cognitive Impairment (MCI) to AD did not significantly differ between males 
and females between the ages 70-79. After the age of 80, however, higher rates of 
conversion were found in females (Roberts et al., 2012). Beam and colleagues examined 
the incidence rate of AD in 16,926 females and males in The Swedish Twin study. They 
found the incidence rate to be greater in females after age 85 for AD and all-cause 
dementia (Beam et al., 2018). However, other studies have failed to report a sex 
difference in AD incidence. Hebert and colleagues (2001) examined incidence of AD in a 
population of 3,089 older adults, aged 65 and older, who were dementia free at baseline 
from the Established Populations for Epidemiologic Study of Elderly (EPESE) Project of 
East Boston. Six hundred forty-two individuals developed dementia over three years. The 
authors used life tables to estimate incidence for males and females for a hypothetical 
sample of 100,000 for each sex. They found that age-specific incidence of AD did not 
differ in males and females (Hebert et al., 2001). In addition, they found that the 




authors concluded that the excess number of females with AD was due to longevity rather 
than other sex-specific factors (Hebert et al., 2001). Similarly, a study examining 1,236 
community dwelling adults aged 55 and older, from the Baltimore Longitudinal Study of 
Aging (BLSA), found no significant difference in AD incidence rates between males and 
females over a 13-year follow-up period (Hebert et al., 2001). However, there was a trend 
for females to have a 10% higher incidence of AD than males (p=.065) of similar age and 
educational attainment (Kawas et al., 2000). The studies above present mixed results in 
the incidence of AD for males and females, though differences in the ages of the samples 
and duration of follow-ups may contribute to discrepant findings.  
Sex differences have also been observed in the prodromal stage of dementia, or 
MCI (Csukly et al., 2016). Several forms of MCI have been identified: amnestic MCI in 
which memory loss is predominant and non-amnestic MCI in which cognitive domains 
other than memory are impaired (e.g., visuospatial abilities) (Csukly et al.,2016). In at 
least one sample, males were found to have a higher prevalence rate of non-amnestic 
MCI (20%) compared to females (10.9%; Roberts et al, 2012). In addition, females 
appear to have greater MCI incidence rates in older ages than males (Roberts et al., 
2012). Non-amnestic MCI has been associated with higher conversion rates to non-AD 
dementias, while amnestic MCI is considered a prodrome to AD (Petersen, 2004). Thus, 
some of the sex discrepancies in AD rates at later ages may be explained in part by 
greater prevalence of MCI in females at older ages, and possibly with males having 
greater non-amnestic MCI.  
Recent research suggests that hormonal changes in females in mid-to-late life also 




that accompany menopause include reduced estrogen levels, which have implications for 
various physiological processes in the brain. For example, menopausal and 
perimenopausal females have reduced brain glucose metabolism, increased development 
of amyloid plaques, and reduced production of brain-derived neurotrophic factor (BDNF; 
a protein that is integral to synaptic development and plasticity) (Mosconi et al., 2010)). 
These changes have been postulated to contribute to the increased risk of AD amongst 
females (Mielke et al., 2014). In addition, structural changes such as reduced gray matter 
and white matter in areas of the brain associated with AD (e.g., the default mode 
network) also have been associated with menopause (Mosconi et al., 2010). Furthermore, 
hormone therapy, initiated near the onset of menopause is associated with a reduction in 
risk for AD in females (Zandi et al., 2002; Whitmer et al., 2010), though clinical trials 
have not borne conclusive results (Shumaker et al., 1998; Harman et al., 2005). While the 
specific mechanisms are unclear, the above research suggests physiological changes in 
relation to menopause in females that may also contribute to the sex differences in the 
rates of the disease. 
Family History of Alzheimer’s Disease, Maternal/Paternal  
Transmission, and Sex Differences in AD Risk 
Several studies have found increased risk of developing AD in those individuals 
with a positive family history of the disease (van Duijin et al., 1991, Fratiglioni et al., 
1993; Cannon-Albright et al., 2019). A positive parental history of AD has been 
associated with 4-10 times greater risk of developing AD or other dementias in the 
proband (van Duijn et al., 1991; Fratiglioni et al.,1993). In a re-analysis of seven case 




of AD for those with at least one first-degree relative with all-cause dementia (van Duijn 
et al., 1991). In addition, they examined age of onset in relation to risk and found the 
relative risk decreased with increasing age of onset. Van Duijn and colleagues (1991) 
also found those with two or more first-degree relatives had more than seven times the 
risk of developing AD (RR=7.5; van Duijn et al., 1991) than those without a family 
history. Another study by Fratiglioni and colleagues (1993) examined the association 
between first-degree relatives with all-cause dementia and risk for developing AD in a 
case-control study. Ninety-eight cases and 216 controls were examined in a population-
based study in Stockholm. The authors found that having at least one first-degree relative 
with all-cause dementia was associated with a 3.2-fold relative risk of developing AD 
compared to those without a first-degree relative with dementia (Fratiglioni et al., 1993). 
The above studies did not examine extended family history (e.g., second-or-higher degree 
relatives) or sex differences amongst the proband.  
A recent study by Cannon-Albright and colleagues (2019) examined extended 
family history and sex differences associated with the risk of developing AD. They found 
in state-wide death certificates of older adults in Utah, family history of at least one first-
degree relative doubled the relative risk of developing AD. The relative risk nearly 
doubled beyond that (RR=3.98) with having two first-degree relatives; having four first-
degree relatives further increased the risk 14-fold (Cannon-Albright et al., 2019). 
Furthermore, the authors found sex differences among maternal/paternal lines. Having a 
first-degree male relative with AD was associated with a greater risk compared to having 
a first-degree female relative with AD (Cannon-Albright et al., 2019). However, the 




degree relatives (i.e., mother’s brother; RR=1.58); paternal second-degree relative (i.e., 
father’s brother; RR=0.95) was not significant. The maternal association was only found 
amongst analyses examining second-degree relatives and not those examining first- or 
third-degree relatives. Other studies have reported a stronger association with maternal 
transmission of risk for AD than paternal transmission for both male and female probands 
(Honea et al., 2012; Mosconi et al., 2007; Mosconi et al., 2010). 
A recent study by Honea and colleagues (2012) examined biomarkers of AD in 
403 individuals with vs. without a family history of AD in a cross-sectional analysis of 
participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. The 
participants were classified as having normal cognition, MCI, or AD. They found that a 
maternal family history of AD was associated with increased uptake of Pittsburgh B 
Compound (PiB; a biomarker reflecting beta amyloid deposition) in the parietal and 
sensorimotor cortices and the precuneus areas of the brain in all participants, regardless 
of cognitive status. (Note, the degree of PiB uptake did differ by cognitive status) (Honea 
et al., 2012). Additionally, those with a maternal family history of AD had reduced 
cerebrospinal fluid (CSF) amyloid-beta (Aβ) levels and increased tau/Aβ ratio, both 
known biomarkers of AD, compared to participants with a paternal family history only or 
no family history (Honea et al., 2012). Another study of cognitively normal older adults 
found that those with a maternal family history of AD showed reduced glucose 
metabolism in the medial-temporal lobe and parietotemporal, posterior cingulate, and 
frontal cortices compared to those with a paternal family history (Mosconi et al., 2007). 
In a follow-up to this study, the authors found that cognitively normal individuals at 




metabolism over a two-year period compared to those with a paternal or negative family 
history (Mosconi et al., 2010). These studies suggest greater AD pathology in those with 
a maternal family history of the disease. In contrast, however, Ehrenkrantz and 
colleagues (1999) found in a sample of 1,220 individuals, there was no evidence of 
maternal transmission of the disease but there was evidence of paternal transmission of 
AD. While this is a single study that does not support a maternal transmission, the study 
consisted of a large sample size and an extensive longitudinal follow-up period (up to 15 
years) completed by the Mount Sinai Alzheimer’s Disease Research Center. 
In summary, several studies have reported the significance of a maternal family 
history of AD to be significant for AD risk, although at least one large study reports the 
importance of paternal family history. The above studies differed in sample size, 
geographic locations (lifestyle and cultural factors), determination of dementia diagnosis, 
and method of determining family history. Not examined was whether maternal/paternal 
transmission of AD varied by the sex of the proband or by genetic factors.  
Sex Differences in Apolipoprotein Ɛ4 Allele  
Carriers in Risk for Alzheimer’s Disease 
Sex differences also appear in relation to the genetic risk associated with the 
apolipoprotein E (APOE) gene. Several studies have found a four-fold increased risk of 
developing AD amongst female APOE Ɛ4 carriers compared to female non- Ɛ4 carriers 
(Bretsky et al., 1999; Farrer et al., 1997; Payami et al., 1996). By contrast, male APOE Ɛ4 
carriers reportedly exhibit little-to-no risk compared to male non- Ɛ4 carriers (Bretsky et 
al., 1999), though one study reported that males carrying two copies of the APOE Ɛ4 




(Payami et al., 1996). A study by Corder and colleagues (2004) examined 5,000 autopsies 
of individuals between 25-96 years of age and found an interaction between age, sex, and 
APOE Ɛ4 status. They found that middle-aged female APOE Ɛ4 carriers had more brain 
regions affected by AD pathology than male APOE Ɛ4 carriers. In addition, they found, 
that among AD patients, female APOE Ɛ4-allele carriers (one or 2 copies) presented at 
autopsy with more amyloid plaques and neurofibrillary tangles compared to all non-
carriers and male APOE Ɛ4 allele carriers in earlier Braak stages (a staging system of 
Alzheimer’s neuropathology). However, the sex difference in amyloid plaques and 
tangles were not evident in later Braak stages (Corder et al., 2004). In addition, Fleisher 
and colleagues (2005), in a sample of cognitively normal adults, found greater loss of 
hippocampal volumes in female APOE Ɛ4 carriers compared to male APOE Ɛ4 carriers. 
Other differences in the brains between the sexes have been found in cortical thickness 
and volumes among cognitively normal adults, with a more pronounced loss in female 
APOE Ɛ4 carriers than in male Ɛ4 carriers (Liu et al., 2010). In summary, several studies 
suggest sex differences in AD risk by APOE genotype. However, not explored are 
whether familial transmission (maternal or paternal lines) further influence AD risk 
beyond the apparent sex-specific risk of APOE genotype. Additionally, overall family 
longevity has not been examined in prior studies. 
Differences in Parental longevity and Risk for Alzheimer’s Disease 
As noted earlier, advanced age is the number one risk factor for AD (Guerreiro & 
Bras, 2015), though in extreme old age, risk appears to decline (Andersen et al., 2012; 




females (or regardless of sex) for each year after the age of 65 (Jorm & Jolley, 1998). 
Longevity is related to both genetic and environmental factors (Passarino et al., 2016) 
and exceptional longevity (generally considered over age 86 is associated with reduced 
morbidity including reduced cognitive decline (Andersen et al., 2012). A study by 
Andersen and colleagues (2012) examined nonagenarians (87-99 years of age), 
centenarians (100-104 years of age), semicentenarians (105-109 years of age), and 
supercentenarians (110 and above years of age) and prevalence of at least one age related 
disease (cardiovascular disease, chronic obstructive pulmonary disease, dementia, 
diabetes mellitus, and stroke). The authors found delayed onset of at least one of the 
above age-related disease in those with exceptional longevity (aged 87 and older) 
compared to controls (those between 47-87 years of age without a family history of 
exceptional longevity) (Andersen et al., 2012). They also found significantly reduced 
hazard of morbidity in all advanced age groups compared with controls. The authors 
suggest the reduced hazards with extreme old age indicate compression of morbidity, 
meaning reduced risk of age-related diseases at the upper age ranges of the human life 
span (Andersen et al., 2012). In addition, with respect to cognitive functioning in this rare 
sample, older age was associated with a delay in the onset of cognitive difficulties 
(Andersen et al., 2012). Interestingly, males outperformed females on all cognitive tests 
at all ages (Andersen et al., 2012), which is not a pattern seen at younger ages 
(Sundermann et al., 2016). Similarly, Westendorp and colleagues (2009) examined risk 
of morbidity among familial nonagenarians (two siblings aged 90 and above), sporadic 
nonagenarians (one individual aged 90 and above), and the offspring of both groups. 




compared to sporadic nonagenarians (Westendorp et al., 2009). The authors further 
examined comorbidity rates in the offspring of the familial and sporadic nonagenarians. 
They found that compared to offspring of sporadic nonagenarians, offspring of sibling 
nonagenarians had lower prevalence of myocardial infarction (2.4% vs. 4.1%), diabetes 
mellitus (4.4% vs. 7.6%), hypertension (23.0% vs. 27.5%) and use of cardiovascular 
medications (23.0% vs. 28.9%) (Westendorp et al., 2009). Lipton and colleagues (2010) 
examined exceptional parental longevity and risk of developing AD. They found in a 
sample of community-dwelling, non-demented older adults (at baseline) followed for 23-
years, that those with a parent living longer than age 95 were at 43% reduced risk of 
developing AD compared to those whose parents died prior to age 95 (Lipton et al., 
2010). Thus, it appears that parental exceptional longevity is inversely related to risk of 
AD.  
The above literature review highlights several non-modifiable (e.g., family 
history, APOE allele carrier status, parental longevity) risk factors that may in part 
underlie the sex differences in AD risk. A family history of AD is associated with 
increased risk of developing the disease and this association has been found in both 
immediate and extended family histories (Cannon-Albright et al., 2019), with differences 
depending on the sex of the affected relative (i.e., male first-degree relative increased the 
risk of developing AD in the proband compared to a female first-degree relative) and 
opposite effects amongst affected second-degree relatives (Cannon-Albright et al., 2019). 
While this study had strengths in the ability to examine extended family histories, a 
significant limitation was the reliance on death certificates for ascertainment of AD 




1994). Many studies report greater risk of AD with maternal transmission (Honea et al., 
2012; Mosconi et al., 2007; Mosconi et al., 2010, and an association with AD biomarkers 
in persons without dementia (Honea et al., 2012; Mosconi et al., 2007; Mosconi et al., 
2010). However, at least one large study found greater risk of AD amongst probands with 
a paternal history (Ehrenkrantz et al., 1999). Sex differences are also found related to 
APOE genotype, with female APOE Ɛ4 carriers being at greater risk for AD than their 
non-Ɛ4 counterparts (Bretsky et al., 1999; Farrer et al., 1997; Payami et al., 1996). 
Amongst males, APOE Ɛ4 homozygotes are at greater risk for AD (Payami et al., 1996). 
While in general, advanced age is a risk factor for AD, exceptional longevity is inversely 
related to AD risk (Andersen et al., 2012). At least one study found exceptional longevity 
was associated with reduced risk of AD in offspring (Lipton et al., 2010). In the literature 
published to date, it is unclear how the above factors (family history, APOE genotype, 
and parental longevity) collectively or in interactions influence AD risk in males and 
females. Furthermore, it is unknown how these factors are associated with modifiable 
vascular risk factors for AD. In the section below, modifiable cardiovascular risk factors 
are discussed in relation to sex differences.  
Modifiable Health-Related Cardiovascular  
Risk Factors for Alzheimer’s Disease 
A large number of observational studies have identified several modifiable risk 
factors for AD, including cardiovascular disease (CVD), diabetes mellitus, metabolic 
syndrome, and obesity (Barnes & Yaffe, 2011). In addition, hypertension, 
hypercholesterolemia, low physical activity, atrial fibrillation, stroke, and non-




fatty acids) have also been associated with the development of AD pathology in the brain 
(de Bruijn & Ikram, 2014). In a meta-analysis, Barnes and Yaffe (2011) concluded that 
mid-life hypertension (OR=1.61), mid-life obesity (RR=1.6) and diabetes (RR=1.39) 
contributed to a significant portion of the cases of AD worldwide (Barnes & Yaffe, 
2011). CVD interactions with APOE have also been reported in AD risk (Barnes & 
Yaffe, 2011). Further, a Swedish study of identical and fraternal twins found that non-
stroke CVD was associated with a two-fold increased risk of developing AD in those 
individuals carrying the APOE Ɛ4 allele; noncarriers of the Ɛ4 allele were not at greater 
risk. The study also found that the twin with dementia was approximately two times more 
likely to have CVD than the twin without dementia (OR=1.86; Eriksson et al., 2010). 
Gottesman and colleagues (2017), found in a bi-racial sample of 15,744 black and white 
older adults, those with a history of midlife diabetes, prehypertension (systolic pressure = 
120-139 mm Hg and diastolic pressure = 80-89 mm Hg), and hypertension (systolic 
pressure=140 and above and diastolic pressure=90 and above) were at a 39% increased 
risk of developing AD in later life. compared to those without these conditions. Diabetes 
was associated with a 77% increased risk of AD (Gottesman et al., 2017). Not well 
studied however, is whether the association between AD and CVD varies by sex, a 
potentially important question given the sex differences in the development of CVD 
(Kautzky-Willer et al., 2016). Females for example, appear to be at greater risk of 
developing CVD through microvascular disease (involvement of small vessels) whereas 
males appear at greater risk of CVD due to obstructive coronary heart disease (Bairey-
Merz et al., 2006). Of note, microvascular changes in the brain have been associated with 




By contrast, obstructive coronary heart disease has not been specifically studied as a risk 
factor for AD. The underlying differences in the cause of CVD between males and 
females may suggest that females are more susceptible to AD (through microvascular 
changes). Kautzky-Willer and colleagues (2016) also found that compared with males, 
females have greater risk for complications from diabetes, including myocardial 
infarction, depression and coronary heart disease, all of which have been identified as 
risk factors for AD (Barnes & Yaffe, 2011). Depending on the underlying cause of 
cardiovascular disease, sex may be an important consideration. Despite the large number 
of studies examining vascular risk factors and AD, few have examined sex differences in 
AD risk. 
The above literature review summarizes a plethora of studies of risk factors for 
AD, particularly, family history, APOE genotype, advanced age, exceptional longevity, 
and modifiable cardiovascular factors. Some studies have examined sex differences, but 
few have attempted to study whether the above factors have similar associations in males 
and females or examined interaction amongst risk factors. The current project examines 
sex differences in the associations between extended familial maternal and paternal 
lineage of AD and interactions with parental longevity and cardiovascular risk factors and 
conditions within a single population. The Cache County Study on Memory in Aging 
(CCSMA) has conducted dementia surveillance in a sample of 5,092 older adults for up 
to 12 years. Linkage with demographic and health databases through the Utah Population 
Database (UPDB) allowed an enrichment of outcomes and risk factors including 




1. Does extended (4-generations) family history of AD and risk for AD vary by 
the sex of the proband?  
2. Does direct maternal or paternal lineage of AD differentially affect risk for 
AD and does this differ by sex of the proband?  
3. Is parental (maternal and/or paternal) longevity associated with risk for 
developing AD and does this risk vary by sex of the proband?  
4. As an exploratory aim, examine whether cardiovascular risk factors and 
conditions are associated with direct maternal or paternal lineage of AD and 









This study is a secondary data analysis of an extant dataset from the Cache 
County Study on Memory in Aging (CCSMA), supplemented with linked datasets to the 
Utah Population Database (UPDB; Norton et al., 2016), including Medicare Claims data 
(Hanson, Smith, & Zimmer, 2015). CCSMA was a longitudinal study with data collection 
that began in 1995 and ended in 2007. It consisted of four triennial waves to examine 
antecedent risk factors of cognitive decline and dementia (Miech et al., 2002). All but one 
of the 5,092 participants of the CCSMA have been linked to the UPDB, a data repository 
that contains over seven million records, including the genealogical records of the 
founders of Utah and their descendants (Norton et al., 2016). The UPDB has been further 
linked to Utah birth and death certificates (Cannon-Albright et al., 2019) and includes 
primary and contributing causes of death. Via the UPDB, health data from Medicare 
Claims from approximately 1992 – 2012 are available for the majority of the CCSMA 
participants (Hanson et al., 2015; Norton et al., 2016). The Medicare claims data utilize 
the International Classification of Diseases (ICD) version 9 for the present study (Hanson 
et al., 2015). This study used data for those participants in CCSMA who have a deep 
genealogical history in the UPDB (two prior generations of information beyond the 
proband) and who have Medicare claims data. The study design and procedures of the 
CCSMA have been described previously (see Miech et al., 2002), and are briefly 




The Cache County Study 
Five thousand six hundred and seventy-seven older adults met eligibility criteria 
for the CCSMA in 1995, which included being a permanent resident of Cache County, 
Utah and over the age of 64. Approximately 90% (5,092) enrolled. The study consisted of 
four triennial waves, which included a multi-stage dementia screening and assessment 
protocol. Baseline cognitive screening and risk factor interviews were conducted at the 
participant’s place of residence. Cognition was assessed using the modified Mini-Mental 
Status Examination (3MS; 100-point measure; Teng & Chui, 1987) which was adapted 
for the study (Tschanz et al., 2002). A proxy interview was given to those participants 
who scored below 60 on the 3MS or could not complete the 3MS, scored below 15 (out 
of 20) on orientation questions, or were otherwise deemed unreliable (Breitner et al., 
1999). The proxy interview included a rating of the subject’s cognitive status using the 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE; Jorm & Jacomb, 
1989). Participants who scored below a cutoff of 87 on the 3MS or above a 3.27 on the 
IQCODE were sent to the second stage, a telephone interview, with a knowledgeable 
informant using the Dementia Questionnaire (DQ). Based on the interview, those subjects 
who were rated as significantly cognitively impaired or with dementia or who were 
members of a designated panel of participants to complete all stages of screening, were 
sent for clinical assessment (CA). The CA consisted of a registered nurse (RN) interview 
with a knowledgeable informant regarding the participant’s history of cognitive 
symptoms, medical history, and current medications. The participant also received a 
physical examination, which consisted of anthropomorphic measurements, blood pressure 




psychometrist (Breitner et al., 1999). The results of the CA were reviewed at an initial 
diagnostic conference led by a study physician and a preliminary diagnosis of dementia 
was rendered using the Diagnostic Statistical Manual-III-Revised (DSM-III-R) criteria 
(American Psychiatric Association [APA], 1987). A diagnosis of AD was assigned if the 
subject met criteria from the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) (McKhann et al., 1984) and that of vascular dementia if the subject 
met criteria from the NINCDS-the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (AIREN; Román et al., 1993). Criteria for other 
dementias followed standard research diagnostic criteria at the time (Breitner et al., 
1999). A follow-up CA (at approximately 18 months) was requested for those with a 
diagnosis of a dementia or its prodrome. Neuroimaging and laboratory studies were 
requested for those individuals with diagnoses of dementia or prodromal AD in order to 
rule out other causes of cognitive impairment (Breitner et al., 1999). An independent 
assessment was also conducted by a study physician. A final clinical diagnosis of 
dementia was determined at a consensus conference with a panel of clinical experts 
including a board-certified neurologist, geropsychiatrists, clinical neuropsychologists, 
and a cognitive neuroscientist. Presence of dementia was determined based on the 
participant’s performance on the CA, DSM-III-R criteria, physician CA, and laboratory 
results and neuroimaging (Breitner et el., 1999). A classification of non-case was defined 
as those who received a “non-case” diagnosis based on the CA, or lacking a CA, were 
screen negative at prior stages of dementia screening. Age of onset for dementia was 




dementia based on the chronological development of cognitive and functional 
impairment. All study procedures were approved by the Institutional Review Boards at 
Utah State University, Duke University, and the John Hopkins University. With the 
completion of all four waves, 942 cases of dementia were identified, 546 (58%) with AD. 
CCSMA data were supplemented with data from Medicare claims from 1992 to 2012, 
and death certificates from 1909 to 2019, for an additional 209 cases of AD. See section 
below on The Utah Population Database and Medicare Claims for detailed procedures.  
CCSMA Derived Family History of Alzheimer’s Disease and Vascular Factors 
Family history of AD was assessed through a structured interview and 
administered at baseline and at subsequent waves. The interview ascertained information 
about the participants’ biological parents and siblings and history of memory problems. 
An endorsement of memory problems for each family member was followed up with 
questions of the onset (sudden or gradual), course being progressive or static, and 
whether the problems resulted in limitations in activities of daily living. A final question 
asked if a physician diagnosed the cause of the memory issue. Each relative was 
classified as having suspected AD if a physician had diagnosed AD, or lacking a 
diagnosis, if the memory problems had worsened over time, and caused limitations with 
daily activities. If a first-degree relative died before age 50 and did not have dementia, 
that person’s information was coded as missing. A study participant was classified as 
having a positive family history of AD if at least one first-degree relative was categorized 
as having suspected AD (Hayden et al., 2009). Maternal and paternal family histories 




with the specific questions used to derive family history of AD. The UPDB linkage with 
death certificates for extended genealogies supplemented family history information (see 
Utah Population Database). Overall family history of AD and maternal and paternal 
family histories were categorized using a combination of CCSMA self-report and 
supplemented with data from the UPDB (see The Utah Population Database). 
Cardiovascular risk factors were obtained in the context of a medical and 
medication risk factor interview conducted at each wave of the CCSMA. History of 
stroke was ascertained by the question, “Has a doctor or nurse ever told you that you had 
a stroke?” Hypertension was ascertained through the question, “Have you been told by a 
doctor that you had hypertension or have you been treated for hypertension?” High 
cholesterol was asked with the question “Have you ever been told by a doctor you had 
high blood cholesterol/triglycerides or have you ever been treated for high blood 
cholesterol/trigylcerides?” Myocardial infarction was collected through the question 
“Have you ever had a heart attack, a myocardial infarction, or a coronary thrombosis?” 
Diabetes was ascertained through the question “Have you ever been told by a doctor you 
had diabetes or have you been treated for diabetes?” Coronary Artery Bypass surgery was 
ascertained through the question “Have you ever had a coronary bypass surgery?” 
Appendix B presents the medical history questionnaire with the specific questions 
associated with cardiovascular and related conditions. Additional risk factors and 





The Utah Population Database 
All but one of the participants of the CCSMA has been linked to the UPDB 
(Norton et al., 2016). The UPDB is a computerized genealogy of founders of Utah and 
their descendants (Cannon-Albright, 2008; https://uofuhealth.utah.edu/huntsman/utah 
-population-database/). The database includes more than 11 million residents of Utah and 
their relatives, of which 3 million individuals have at least 3 generations of genealogy 
linked to the original Utah pioneers. Of the 3 million, 1.3 million have genealogy data 
from at least 12 of 14 immediate ancestors including both parents, all four grandparents, 
and at least six great-grandparents (Cannon-Albright et al., 2019). The genealogy data 
have also been linked with the Utah Death Certificates from 1904 to 2019 and include the 
primary cause of death using International Classification of Diseases (ICD)- 9th edition 
and ICD-10 codes (Cannon-Albright et al., 2019). Additionally, the UBPD has been 
linked to health care registries such as Utah Cancer Registry and Medicare Claims. 
Further information about the UPBD can be accessed at https://uofuhealth.utah.edu 
/huntsman/utah-population-database/data/.  
Medicare Claims Database 
Through the extensive linkage of the UPDB, there is access to Medicare claims 
data that were submitted with ICD-9 conditions from the Centers for Medicare and 
Medicaid services (CMS). Medicare offers health insurance for individuals aged 65 or 
older to all citizens or permanent residents of the US. Data for this project used Medicare 
claims that were available between 1992 to 2012. The ICD-9 billing codes were sought to 




the following cardiovascular risk factors and conditions: hypertension (ICD-9 codes 
401.1, 401.9), hyperlipidemia (272.39), diabetes mellitus (250, 205.12, 205.02), obesity 
(278, 278.01), myocardial infarction (410.01-410.91; 412), stroke (433.01, 433.11, 
433.21, 433.31, 433.81, 434.01, 434.11, 435.8, 435.9), atrial fibrillation (427.31) and 
other arrythmias (427, 427.1, 427.2, 427.32, 427.41, 427.42, 427.69, 427.61, 472.81, 
427.89), congestive heart failure (428), hypothyroidism (244.9), atherosclerosis (440.9, 
440.8, 437, 440), and metabolic syndrome (277.7). In order to accept a claims diagnosis 
for AD, criteria by Nair and colleagues (2018) were followed. Specifically, having at 
least two claims of AD (331.0) at least 18 months apart (Nair et al., 2018). For vascular 
risk factors and conditions, a single claim for an ICD-9 code was accepted as presence of 
a condition. In order to be considered a risk factor, the cardiovascular condition had to 
predate the age of diagnosis of AD.  
Extended Maternal and Paternal Family History 
Family history was expanded upon by using the UPDB’s linkage with the state’s 
vital statistics database. For those with missing information on parental history regarding 
cognitive status, cause of death codes related to AD and related dementias (ICD-9 code 
331.0) were used. Individuals with AD as a primary or contributing factor of death were 
coded as a positive family history of the disease. Second, third, and fourth generation 
family histories of AD were also ascertained in the same manner.  
Exceptional Parental Longevity 
Parental longevity was determined using the CCSMA family history interview 




paternal longevity, with the following cut points: those individuals who survived to age 
87 and older were classified as “exceptional longevity”.  
Other Variables 
Age at study entry (Wave 1), sex, and years of formal education were ascertained 
through the CCSMA baseline interview. APOE genotype was available on 97% (4932) of 
the participants (Breitner et al., 1999). These variables were used as covariates in 
statistical models as described below. 
Statistical Analyses  
Inclusion criteria for the current analyses were outcomes of AD diagnosis or non-
case (other forms of dementia and mild cognitive disorders such as MCI were excluded) 
and family history information sufficient to determine family history of AD and maternal 
and paternal longevity.  
Descriptive statistics were used to characterize the sample with respect to 
demographic attributes for those with a diagnosis of AD compared to non-cases. Group 
differences were examined using Analysis of Variance (ANOVA) for continuous 
variables and chi-square or Fisher’s exact tests for categorical variables.  
Overall, to examine the association of each risk factor and the outcome of AD, 
used binary logistic regression. Model building proceeded in which predictor variables 
were examined systematically. First, variables were entered into the model to examine 
main effects, followed by the inclusion of interaction terms. Those predictor variables 
that were considered theoretically necessary or significant in the model at the p <.05 were 




allele, age at baseline, and education. To explore a non-linear association between age 
and AD risk, a quadratic term for age (age2) was also examined in each model. The 
models were compared using r-squared, ANOVA, Akaike’s Information Criteria (AIC), 
and Bayesian Information Criteria (BIC) to determine the goodness of fit. The 
performance package in R (Lüdecke et al., 2021) was used to compare each model’s 
overall quality and goodness of fit through r-squared, root mean squared error, interclass 
correlation, AIC, and BIC in one comparison table and provided a rank order list of the 
models. The final model retained for each research question included the predictor 
variables that met the criteria described above (statistical significance or theoretical 
importance) and those models that provided the best goodness of fit while being most 
parsimonious model given the above criteria. All statistical analyses were conducted in R 
Studio R-Version 4.0.4 (RStudio Team, 2021).  
To address research question one, binary logistic regressions (separate models for 
sex) were used to examine extended family history of AD and risk for AD. Predictors 
included AD classification for first-degree relative (parents, siblings, and offspring), 
second degree relative, and third degree relative (each variable contained any ancestor 
within that degree that had a diagnosis of AD) associated with risk of AD in the proband. 
An interaction between APOE Ɛ4 status by family history of AD was also tested in the 
models.  
To address research question two, binary logistic regression models (separate 
models for sex), using dichotomous direct maternal and paternal lineage of AD (see 
Appendix C for an illustration of maternal and paternal lineages), were used to examine 




were tested in the models: 1) direct maternal lineage by direct paternal lineage of AD 2) 
APOE Ɛ4 status by direct maternal lineage of AD; and 3) APOE Ɛ4 status by direct 
paternal lineage of AD.  
To address research question three, binomial logistic regression models (separate 
models for sex), using separate dichotomous variables for maternal exceptional longevity 
and paternal exceptional longevity (or not), were used to examine whether each was 
associated with risk of developing AD. The following interactions in predicting AD 
outcome were also examined: 1) maternal exceptional longevity by APOE Ɛ4 status; 2) 
paternal exceptional longevity by APOE Ɛ4 status; and 3.) maternal exceptional longevity 
by paternal exceptional longevity.  
The last research question concerned whether cardiovascular risk factors and 
conditions modified any associations between direct maternal/paternal lineage of AD and 
AD risk in the proband, and whether there were sex differences in these relationships. 
Vascular variables were classified as a risk factor if the age at first Medicare claim or age 
at first reported diagnosis of the condition in CCSMA predated the age of onset of AD. 
Metabolic syndrome was removed as a risk factor as individuals with a Medicare claim 
diagnosis (n=59) did not meet this criterion. Given the large number of health conditions, 
frequencies were examined, and a tetrachoric correlation matrix (Revelle, 2020; 
providing an inferred Pearson’s r for binary variables) was used to determine if each 
binary cardiovascular risk factor was highly correlated (Revelle, 2020). To reduce issues 
with multicollinearity in the statistical models, those significantly correlated with one 
another, a tetrachoric r of at least .60 (Frost, 2020), and determined to have a biological 




dysrhythmias were collapsed as was cholesterol/triglycerides and atherosclerosis. To 
quantitatively examine the severity of multicollinearity among the cardiovascular 
variables, variance importance factor analysis provided an index measure of how much 
variance of the estimated regression coefficient was increased due to collinearity 
(Akinwande et al., 2015; cutoff was less than 5). None of the cardiovascular risk factors 
exceeded the cutoff of five in the variance importance factor analysis; thus, all were 
retained. The final cardiovascular variables included: CVA, diabetes (DM) mellitus, 
hypertension (HTN), congestive heart failure (CHF), 
triglycerides/cholesterol/atherosclerosis (chol/athero), atrial fibrillation and other 
dysrhythmias (afib/dysrhythmias), hypothyroidism, and myocardial infarction (MI). The 
cardiovascular variables that remained highly correlated (r = 0.6) were tested in separate 
models (e.g., afib/dysrthymias and hypothyroidism). Given the number of cardiovascular 
risk factors remaining, statistical methods were employed to enhance prediction accuracy 
and interpretation of the vascular variables through random forest and least absolute 
shrinkage and selection operator (lasso regression). Random forest is a machine learning 
technique that helps examine complex relationships between a set of predictor variables 
and the outcome variable (Breiman, 2001). Random forest utilizes a decision tree, but 
reduces the increased variance associated with having a single decision tree by using 
multiple decision trees to produce a more accurate prediction related to the outcome 
variable (Breiman, 2001). This is obtained by a process of bootstrapping samples of the 
original dataset, which are then used to build decision trees that are averaged to provide a 
prediction of the best fitting predictors for the outcome variable by providing a mean 




variable selection and regularization. It provides a value (Lambda) that produces the 
lowest possible mean squared error and those variables that survive a penalty, are 
retained to help with variable reduction (Tibshirani, 1996). Random Forest and Lasso 
regression are statistical methods that provided a systematic way of removing variables 
from the model (Breiman, 2001; Tibshirani, 1996). The lasso regression and random 
forest analyses were conducted in tandem; the predictor variables were then compared. 
The predictor variables that overlapped in both analyses were considered quantitatively 
as the most predictive outcome variables. Thus, for the final research question, the 
starting point was the final model in research question 2. This model (separate models for 
sex) was used as the base model. Vascular factors that were deemed to be highly 
predictive in the models were added. After the inclusion of each of the vascular factors 
into the base model, the following interactions were examined: 1) each vascular risk 
factor by direct maternal lineage of AD 2) each vascular risk factor by direct paternal 









There were 3677 individuals who met eligibility criteria. Excluded (from the 
5092) were 1,071 individuals who were diagnosed with other forms of dementia or mild 
cognitive disorder (e.g., MCI), 134 individuals who had missing family history data, 209 
individuals with missing maternal and paternal longevity data, and one individual who 
was not linked to the UPDB. The resulting sample consisted of 98.0% white individuals 
and 58.7% females. Mean (SD) age at baseline was 75.75, SD= 7.11. There were 825 
individuals diagnosed with AD, 686 of whom had received a diagnosis from CCSMA, 
126 from their death certificate, and 83 from Medicare claims. Compared to males, 
females were more likely to have AD (24.9% compared to 18.9% in males) and were 
more likely to have a high school/GED or less than high school education (57.5% 
compared to 44.7.% in males). Mean age of onset of AD for females was 82.62, SD= 6.57 
and 81.61, SD= 6.96, for males. Table 1 presents the baseline characteristics for the 
overall sample by sex.  
Family History and Risk of Alzheimer’s Disease: Female Probands 
Compared to non-case females, those who developed AD were more likely to 
have an APOE Ɛ4 allele (57% compared to 26.2) and a first-degree relative with AD 
(31.9% compared to 19.1%). Table 2 presents the risk factors by cognitive outcome. 
Among females, having a first-degree relative with AD (vs. none) was associated 
with a 66% increase in the odds of developing AD, Odds Ratio (OR) = 1.66, 95% 






Overall Baseline Characteristics by Sex  
Characteristic 
Males 
(n = 1520) 
 Females 
(n = 2157) 
  
n % M SD  n % M SD X2 t 
            
Individual-Level Variables 
Alzheimer’s Disease           18.47**  
Positive AD Diagnosis 287 18.9    538 24.9     
Non-Case 1233 81.1    1619 75.1     
            
Age at baseline   74.98 6.84    76.30 7.25  -5.63** 
            
Education          57.59**  
High School or Less 680 44.7    1240 57.5     
Greater than High School 840 55.3    917 42.5     
            
APOE Ɛ4 Status          0.34  
APOE Ɛ4 Present 480 31.6    702 32.5     
APOE Ɛ4 Absent  1040 68.4    1455 67.5     
            
Family History Variables  
Direct Maternal Lineage of ADa          0.4  
Positive History 186 12.2    248 11.5     
Negative History  1334 87.8    1909 88.5     
            
Direct Paternal Lineage of ADa          1.33  
Positive History 94 6.2    113 5.2     
Negative History  1426 93.8    2044 94.8     
            
First-Degree Relative with ADb          0.4  
At Least One  329 21.6    487 22.6     
None 1191 78.4    1670 77.4     
            
Second-Degree Relative with ADc          0.09  
At Least One  285 18.8    414 19.2     
None 1235 81.2    1743 80.8     
Third-Degree Relative with ADd          2.58  
At Least One  947 62.3    1286 59.6     
None 573 37.7    871 40.4     
At Least One  947 62.3    1286 59.6     
            
Any Relative with AD Extending 
Back 4 Generations 
         0.56  
At Least One  1090 71.7    1521 70.5     
None  430 28.3    636 29.5     
            
Maternal Longevity           0.42  
Survival to age 87 489 32.2    717 33.2     
Survival to age 86 or below  1031 67.8    1440 66.8     
            
Paternal Longevity           0  
Survival to age 87 300 19.7    424 19.7     
Survival to age 86 or below 1220 80.3    1733 80.3     
            
Cardiovascular Variables 
Atrial Fibrillation          0  
Yes  50 3.3    70 3.2     
None 1470 96.7    2087 96.8     
            
Stroke          0.38  
Yes  142 9.3    216 10     
None 1378 90.7    1941 10     
 
 






(n = 1520) 
 Females 
(n = 2157) 
  
n % M SD  n % M SD X2 t 
            
Diabetes Mellitus           7.33*  
Yes 316 20.8    371 17.2     
None 1204 79.2    1786 82.8     
            
Hypertension           59.48**  
Yes  768 50.5    1366 63.3     
None 752 49.5    791 36.7     
            
Cholesterol/Triglycerides          3.4  
Yes  588 38.7    901 41.8     
None 932 61.3    1256 58.2     
            
Obesity           2.01  
Yes  —e —e    12 0.6     
None 1517 99.8    2145 99.4     
            
Hypothyroidism           16.81**  
Yes  41 2.7    120 5.6     
None 1497 97.3    2037 94.9     
            
Myocardial infarction           73.37**  
Yes  344 22.6    258 12     
None 1176 77.4    1899 88     
            
Atherosclerosis          0.78  
Yes  33 2.2    51 2.4     
None 1487 97.8    2106 97.6     
            
Other Dysrhythmias           0.21  
Yes  69 4.5    90 4.2     
None 1451 95.5    2067 95.8     
            
Congestive Heart Failure           8.53*  
Yes  85 5.6    176 8.2     
None 1435 94.4    1981 91.8     
            
Note. N = 3677. AD = Alzheimer’s disease; APOE = apolipoprotein; GED = General Educational Development. 
a Direct Lineage is parents, grandparents and great grandparents extending back three generations. 
b Parents, siblings, offspring 
c Grandparents, grandchildren, half-siblings, aunts/uncles, nieces/nephews 
d First cousins, great grandparents, great grandchildren, great aunts/uncles 
e Subsample size was suppressed because it was under the Health Portability and Accountability Act’s (HIPAA’s) 
threshold for reporting data on this variable.   




age2, education, and the presence of an APOE Ɛ4 allele. P-values for each predictor 
ranged from p =<.001 to .380 (see Table 3). Figure 1 presents a probability plot of risk of 
AD for females with compared to those without a first-degree relative with AD across 
various ages. Probability plots were produced in R (RStudio Team, 2021), and represent 
the division of the odds by one plus the odds. Binary logistic regression models for 
having a second-degree relative only, third-degree relative only, or any relative with AD 
were not significant. The interaction between the presence of an APOE Ɛ4 and each of 
the above family history variables was also not significant (each interaction p > .126).  
Table 2 
 
Predictor Variables by Alzheimer’s disease or Non-Case Outcomes in Female Probands 
Characteristic 
Non-Case 
(n = 1643) 
 Alzheimer’s Disease 
(n = 551) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   75.14 6.84    79.63 7.32  -13.1** 
            
Education          0.11  
High School or Less 942 57.3    321 58.3     
Greater than High School 701 42.7    230 41.7     
            
APOE Ɛ4 Status          119.83**  
APOE Ɛ4 Present  430 26.2    284 51.5     
APOE Ɛ4 Absent  1213 73.8    267 48.5     
            
First-Degree Relative with ADa           38.85**  
At Least One 313 19.1    176 31.9     
None 1330 80.9    375 68.1     
            
Second-Degree Relative with ADb            
At Least One 298 18.1    118 21.4     
None 1345 81.9    433 78.6     
            
Third-Degree Relative with ADc           0.11  
At Least One 960 58.4    327 59.3     
None 683 41.6    224 40.7     
            
Any Relative with AD Extending 
Back Four Generations 
         3.92*  
At Least One 1123 68.4    402 73     
None  520 31.6    149 27     
            
Note. N = 2194. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Parents, siblings, offspring 
b Grandparents, grandchildren, half-siblings, aunts/uncles, nieces/nephews 
c First cousins, great grandparents, great grandchildren, great aunts/uncles 






Females: Binary Logistic Regression With Extended Family History  
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept  -0.21 5.46 -3.83 1 <.001** 8.08-10 1.65-14 3.38-05 
Age, Years 0.40 0.14 2.87 1 .004* 1.48 1.14 1.95 
Age2, Years -0.002 0.0008 -2.19 1 .029* 0.998 0.996 0.998 
APOE Ɛ4 Status 1.26 0.11 11.40 1 <.001** 3.53 2.84 4.38 
Education, High School 
Education or Less 
0.10 0.11 0.88 1 .380 1.10 0.89 1.36 
First-Degree Relative with ADa 0.51 0.12 4.22 1 <.001** 1.66 1.31 2.10 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most 
parsimonious. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Parents, siblings, offspring 
*p < .05. **p < .001. 
Figure 1 
 
Female Probands: First Degree Relative With Alzheimer’s Disease  
 
Note. This figure presents the probability of AD for females without the presence of an APOE Ɛ4 allele and 
with a high school/GED or less education by a first-degree relative with AD (vs. none) across various ages. 




Family History and Risk of Alzheimer’s Disease: Male Probands 
Males with AD compared to non-cases, were more likely to have an APOE Ɛ4 
allele (51.6% vs. 26.8%), a first-degree relative with AD (30.4% compared to 19.2%), a 
third degree relative with AD (66.8% vs. 60.2%), and at least one relative with AD 
extending back four generations (76.8% compared to 69.4). Table 4 presents the predictor 
variables for males by cognitive outcome.  
Table 4 
 
Predictor Variables by Alzheimer’s Disease or Non-Case Outcomes in Male Probands 
Characteristic 
Non-Case 
(n = 1252) 
 Alzheimer’s Disease 
(n = 289) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   75.10 6.86    77.92 7.27  -7.9** 
            
Education          1.76  
High School or Less 550 43.9    140 48.4     
Greater than High School 702 56.1    149 51.6     
            
APOE Ɛ4 Status          65.39*  
APOE Ɛ4 Present  336 26.8    149 51.6     
APOE Ɛ4 Absent  916 73.2    140 48.4     
            
First-Degree Relative with ADa           16.88**  
At Least One 241 19.2    88 30.4     
None 1011 80.8    201 69.6     
            
Second-Degree Relative with ADb          1.74  
At Least One 224 17.9    62 21.5     
None 1028 82.1    227 78.5     
            
Third-Degree Relative with ADc           3.99*  
At Least One 754 60.2    193 66.8     
None 498 39.8    96 33.2     
            
Any Relative with AD Extending 
Back Four Generations 
         5.88*  
At Least One 869 69.4    222 76.8     
None  383 30.6    67 23.2     
            
Note. N = 1541. AD = Alzheimer’s Disease; APOE = Apolipoprotein; GED = General Educational Development. 
a Parents, siblings, offspring 
b Grandparents, grandchildren, half-siblings, aunts/uncles, nieces/nephews 
c First cousins, great grandparents, great grandchildren, great aunts/uncles 




Among males, having a first-degree relative with AD (vs. none) was associated 
with a 58% increase in the odds of developing AD, OR = 1.58, 95% CI [1.16-2.13], p = 
.003, when controlling for baseline age, education, and the presence of an APOE Ɛ4 
allele. P-values for each predictor ranged from p=<.001 to .414 (see Table 5). Figure 2 
presents a probability plot of risk of AD for males with a first-degree with AD compared 
to those without a first-degree relative with AD across various ages. Binary logistic 
regression models for having a second-degree relative only, third-degree relative only, or 
at least one relative with AD extending back four generations were not significant. The 
interaction between presence of an APOE Ɛ4 allele and each of the above family history 
variables was also not significant (each interaction p > .230)  
Table 5 
 
Males: Binary Logistic Regression With Extended Family History  
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept  -8.55 0.80 -10.64 1 <.001** 0.0001 0.00004 0.0009 
Age, Years 0.08 0.01 8.53 1 <.001** 1.09 1.07 1.11 
APOE Ɛ4 Status 1.19 0.14 8.40 1 <.001** 3.30 2.50 4.36 
Education, High School 
Education or Less 
0.12 0.14 0.82 1 .414 1.12 0.85 1.48 
First-Degree Relative with ADa 0.45 0.16 2.93 1 .003* 1.58 1.16 2.13 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most 
parsimonious. AD = Alzheimer’s Disease; APOE = Apolipoprotein.  
a Parents, siblings, offspring 






Male Probands: First Degree Relative With Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for males without the presence of an APOE Ɛ4 allele and 
with a high school/GED or less education by a first-degree relative with AD (vs. none) across various ages. 
First-degree relatives include parents, siblings, and offspring. AD = Alzheimer’s Disease. 
Risk of Alzheimer’s Disease for Direct Maternal and Paternal Lineage of 
Alzheimer’s Disease Among Female Probands  
Female probands with AD were more likely to be older, have an APOE Ɛ4 allele 
(51.7% compared to 26.1%) and a direct maternal lineage of AD (13.9% vs. 10.5%) 
compared to non-case females. Table 6 presents the predictor variables for direct 






Predictor Variables Including Maternal and Paternal Lineage of Alzheimer’s Disease 
and Cognitive Outcomes in Female Probands 
Characteristic 
Non-Case 
(n = 1707) 
 Alzheimer’s Disease 
(n = 567) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   75.13 6.86    79.68 7.30  -13.47** 
            
Education          0.18  
High School or Less 1304 57.3    330 58.2     
Greater than High School 920 42.7    237 41.8     
            
APOE Ɛ4 Status          125.48**  
APOE Ɛ4 Present  446 26.1    293 51.7     
APOE Ɛ4 Absent  1261 73.9    274 48.3     
            
Direct Maternal Lineage of ADa          4.69*  
Positive History 179 10.5    79 13.9     
Negative History  1528 89.5    488 86.1     
            
Direct Paternal Lineage of ADa          3.24  
Positive History 82 4.8    39 6.9     
Negative History  1625 95.2    528 93.1     
            
Note. N = 2274. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Direct Lineage is parents, grandparents and great grandparents extending back three generations. 
*p < .05. **p < .001.  
Compared to females with no family history of AD, direct maternal (but not 
paternal, p = .101) lineage of AD was associated with a 56% increase in the odds of 
developing AD, OR = 1.56, 95% CI [1.14-2.13], p = .005, when controlling for age at 
baseline, age2, education, and presence of the APOE Ɛ4 allele. Figure 3 presents a 
probability plot of risk of AD for females with a direct maternal lineage of AD across 
various ages. P-values for each predictor variable ranged from p =<.001to .427 (see 
Table 7). The interaction between the presence of an APOE Ɛ4 and the above direct 
lineage variables was non-significant as was the interaction between direct maternal and 






Females: Binary Logistic Regression With Direct Maternal and Paternal Lineage of 
Alzheimer’s Disease 
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept -22.91 5.38 -5.05 1 <.001** <0.001 0.000 0.000 
Direct Maternal Lineage of AD 0.45 0.22 2.43 1 .005* 1.56 1.14 2.13 
Direct Paternal Lineage of AD 0.37 0.22 1.79 1 .101 1.44 0.92 2.22 
APOE Ɛ4 Status 1.26 0.11 10.77 1 <.001** 3.53 2.86 4.39 
Education, High School 
Education or Less 
0.08 0.11 1.17 1 .427 1.09 0.88 1.34 
Age, Years 0.44 0.14 4.11 1 .001* 1.55 1.19 2.03 
Age2, Years -0.002 0.0009 -3.52 1 .012* 0.998 0.996 0.999 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious. 
AD = Alzheimer’s Disease; APOE = Apolipoprotein.  
*p < .05. **p < .001. 
Figure 3 
 
Direct Maternal Lineage of Alzheimer’s Disease in Females  
 
Note. This figure presents the probability of AD for females without the presence of an APOE Ɛ4 allele and 
with a high school/GED or less education by a direct maternal lineage of AD (vs. none) across various 




Risk of Alzheimer’s Disease for Direct Maternal and Paternal Lineage of 
Alzheimer’s Disease Among Male Probands 
Compared to male non-cases, males with AD were more likely to be older at 
baseline and have an APOE Ɛ4 Allele. Predictor variables for maternal and paternal direct 
lineage of AD for male probands is presented in Table 8.  
Table 8 
 
Predictor Variables Including Maternal and Paternal Lineage of Alzheimer’s Disease 
and Cognitive Outcomes in Male Probands 
Characteristic 
Non-Case 
(n = 1314) 
 Alzheimer’s Disease 
(n = 299) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   75.10 6.85    77.94 7.31  -7.94** 
            
Education            
High School or Less 796 44.4    143 47.8   1.47  
Greater than High School 995 55.6    156 52.2     
            
APOE Ɛ4 Status          71.79**  
APOE Ɛ4 Present  348 26.5    155 51.8     
APOE Ɛ4 Absent  966 73.5    144 48.2     
            
Direct Maternal Lineage of ADa          0.81  
Positive History 157 11.9    42 14     
Negative History  1157 88.1    257 86     
            
Direct Paternal Lineage of ADa          0.46  
Positive History 76 5.8    21 7     
Negative History  1238 94.2    278 93     
            
Note. N = 1613. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Direct Lineage is parents, grandparents and great grandparents extending back three generations. 
*p < .05. **p < .001.  
Among males, neither maternal, OR= 1.38, p= .19, nor paternal, OR= 1.69, p= 
.07, lineage of AD was associated with risk of AD in the proband. However, an 
interaction between maternal and paternal lineage was significant at a trend level p = .054 
level, OR= 0.22, 95% CI [0.05-0.93], with males who had both a direct maternal and 




males with neither. This result was maintained with the following covariates: age at 
baseline, presence of an APOE Ɛ4 allele, and education. P-values for the covariates 
ranged from p= < .001 to .433 (see Table 9). Figure 4 presents a probability plot of the 
risk of AD for males from the model with the interaction between paternal and maternal 
lineage of AD. The interactions between the presence of an APOE Ɛ4 allele and each of 
the family history variables were not significant (each interaction p> .117). 
Table 9 
 
Males: Binary Logistic Regression With Direct Maternal and Paternal Lineage of 
Alzheimer’s Disease  
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept -8.76 0.80 -10.96 1 <.001** 0.0001 0.000 0.000 
Direct Maternal Lineage of AD 0.27 0.21 1.30 1 .193 1.31 0.86 1.96 
Direct Paternal Lineage of AD 0.52 0.21 1.78 1 .074 1.69 0.93 2.98 
APOE Ɛ4 Status 1.23 0.30 8.90 1 <.001** 3.48 2.65 4.59 
Education, High School 
Education or Less 
0.11 0.14 0.78 1 .433 1.11 0.85 1.47 
Age, Years 0.09 0.14 8.94 1 <.001** 1.09 1.07 1.11 
Direct Maternal Lineage of AD 
× Direct Paternal Lineage of 
AD 
-1.41 0.73 -1.92 1 .054 0.22 0.05 0.93 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious. 
AD = Alzheimer’s Disease; APOE = Apolipoprotein.  






Direct Parental Lineage of Alzheimer’s Disease in Males  
 
Note. This figure presents the probability of AD for males without the presence of an APOE Ɛ4 allele and 
with a high school/GED or less education by a direct maternal and/or paternal lineage of AD (vs. none) 
across various ages. This model is not the most parsimonious, however, and includes a trend level 
interaction between maternal and paternal lineage of AD in male probands. AD = Alzheimer’s Disease.  
Parental Exceptional Longevity and Alzheimer’s Disease Among Female Probands  
Females with AD compared to female non-cases, were more likely be older 
(79.72 compared to 75.16) and have a first-degree relative with AD (32.5% vs. 19.3%), 
but did not differ by parental longevity. Table 10 presents the predictor variables for 






Predictor Variables for Parental Longevity and Cognitive Outcomes in Female Probands 
Characteristic 
Non-Case 
(n = 1619) 
 Alzheimer’s Disease 
(n = 538) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   75.16 6.85    79.72 7.36  -12.64** 
            
Education          0.1  
 High School or Less 1240 57.5    313 58.2     
 Greater than High School 917 42.5    225 41.8     
            
APOE Ɛ4 Status          113.72  
APOE Ɛ4 Present 702 32.5    276 51.3     
APOE Ɛ4 Absent  1455 67.5    262 48.7     
            
Maternal Longevity           0.78  
Survival to age 87 717 33.2    170 31.6     
Survival to age 86 or 
below 
1440 66.8    368 68.4     
            
Paternal Longevity           0.01  
Survival to age 87 317 19.6    107 19.9     
Survival to age 86 or 
below 
1302 80.4    431 80.1     
            
First-Degree Relative with 
AD (Parents, Siblings, 
Offspring) 
         39.84**  
At Least One 312 19.3    175 32.5     
None  1307 80.7    363 67.5     
            
Parental Longevity          0.05  
Survival to age 87 739 54.4    242 45     
Survival to age 86 or 
below 
880 45.6    296 55     
            
            
Note. N = 2157. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
*p < .05. **p < .001.  
Neither exceptional maternal longevity, OR= 0.96, 95% CI [0.76-1.20], p= .713, 
nor exceptional paternal longevity, OR=1.09, 95% CI [0.83-1.42], p=.537, was associated 
with risk for AD in the proband, when controlling for age at baseline, education, and 
first-degree relative with AD. P-values for the predictor variables ranged from <.001 to 
.713 (see Table 11). The interaction between the presence of an APOE Ɛ4 allele and 




variable were also not significant (each individual p > .597). However, the interaction 
between paternal exceptional longevity and APOE Ɛ4 was significant at trend level, with 
the presence of one or more APOE Ɛ4 alleles and having a longer-lived father being 
associated with 4.59 greater odds of developing AD, OR= 4.59, p=.063.  
Table 11 
 
Females: Binomial Logistic Regression With Maternal and Paternal Longevity and Risk 
of Alzheimer’s Disease 
Parameter b SE Wald df Sig. OR 
OR 95% CI 
Lower Upper 
         
Intercept -9.14 0.62 -14.80 1 <.001** <0.000 <0.001 <0.001 
Maternal Longevity  -0.04 0.12 -0.36 1 .713 0.96 0.76 1.20 
Paternal Longevity  0.08 0.14 0.62 1 .537 1.09 0.83 1.42 
First-Degree Relative with ADa 0.53 0.12 4.40 1 <.001** 1.70 1.34 2.15 
APOE Ɛ4 Status 1.24 0.12 11.13 1 <.001** 3.47 2.79 4.32 
Education, High School 
Education or Less 
0.09 0.11 0.79 1 .429 1.09 0.88 1.35 
Age 0.10 0.01 12.58 1 <.001** 1.10 1.08 1.11 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious. 
AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Parents, siblings, offspring  
*p < .05. **p < .001. 
Parental Exceptional Longevity and Alzheimer’s Disease Among Male Probands 
Males with AD (vs. non-case), were older, more likely to have an APOE Ɛ4 allele 
(59.1% compared to 31.6%) and have a first-degree relative with AD (30.7% compared 
to 19.5%). Table 12 presents the predictor variables for male probands with parental 







Predictor Variables for Parental Longevity and Cognitive Outcomes in Male Probands  
Characteristic 
Non-Case 
(n = 1233) 
 Alzheimer’s Disease 
(n = 287) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   74.29 6.55    77.91 7.28  -7.73** 
            
Education          1.77  
High School or Less 541 43.9    139 48.4     
 Greater than High School 692 56.1    148 51.6     
            
APOE Ɛ4 Status          66.57**  
APOE Ɛ4 Present 480 31.6    149 51.9     
APOE Ɛ4 Absent 1040 68.4    138 48.1     
            
Maternal Longevity           1.21  
Survival to age 87 405 32.8    84 29.3     
Survival to age 86 or 
below 
828 67.2    203 70.7     
            
Paternal Longevity           0.00  
Survival to age 87 243 19.7    57 19.9     
Survival to age 86 or 
below 
990 80.3    230 80.1     
            
First-Degree Relative with 
AD (Parents, Siblings, 
Offspring) 
         16.31**  
 At Least One 241 19.5    88 30.7     
 None  992 80.5    199 69.3     
            
Parental Longevity          0.02  
Survival to age 87 562 45.6    129 44.9     
Non-Longer-Lived 
Parents  
671 54.    158 55.1     
            
Note. N = 1975. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Parents, siblings, offspring 
*p < .05. **p < .001.  
In male probands, there was a significant interaction between APOE Ɛ4 and 
exceptional maternal longevity (p = .020) and a significant interaction between maternal 
and paternal exceptional longevity (p = .041). With respect to the results of APOE Ɛ4 and 
maternal longevity, males who had a long-lived mother and at least one APOE Ɛ4 allele 
had triple the odds of AD, OR=3.15, p = .020, compared to males with neither attribute. 




APOE Ɛ4 allele status across various ages. These results were obtained controlling for 
age at baseline, education, any relative with AD, and paternal longevity. P-values for the 
predictor variables ranged from p= <.001 to .401 (see Table 13).  
Table 13 
 
Males: Binomial Logistic Regression With Maternal and Paternal Longevity and Risk of 
Alzheimer’s Disease 
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept -8.66 0.83 -10.46 1 <.001** <0.001 0.000 0.003 
Maternal Longevity  0.43 0.21 2.03 1 .042* 1.54 1.01 2.33 
Paternal Longevity  0.28 0.20 1.38 1 .171 1.32 0.88 1.97 
First-Degree Relative with ADa 0.46 0.16 2.92 1 .004* 1.58 1.16 2.14 
APOE Ɛ4 Status 1.43 0.17 8.28 1 <.001** 4.17 2.98 5.87 
Education, High School 
Education or Less 
0.12 0.14 0.84 1 .401 1.12 0.85 1.49 
Age, Years 0.08 0.01 8.34 1 <.001** 1.09 1.07 1.11 
Maternal Longevity × APOEƐ4 
Status 
-0.71 0.31 -2.33 1 .020* 0.49 0.27 0.89 
Maternal Longevity × Paternal 
Longevity  
-0.82 0.40 -2.04 1 .041* 0.44 0.19 0.95 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious. 
AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Parents, siblings, offspring  
*p < .05. **p < .001. 
With respect to the interaction between maternal and paternal longevity and risk 
for AD, males with both a maternal and paternal history of exceptional longevity had an 
11% lower odds of developing AD, OR= 0.89, p=.041. These results were obtained in a 
model controlling for baseline age, any relative with AD, education, and presence of an 
APOE Ɛ4 allele (p values ranged from <.001 to .401 for the covariates). See Table 13 for 
the fully adjusted model and parameter estimates. Figure 6 presents a probability plot of 
risk for AD for males by maternal and paternal longevity. The interaction between 






Maternal Longevity and APOE Status in Male Probands and Risk for Alzheimer’s 
Disease 
 
Note. This figure presents the probability of AD for males with a first-degree relative without AD and 
without paternal longevity and with a high school/GED or less education by maternal longevity and APOE 






Maternal and Paternal Longevity in Male Probands and Risk for Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for males with a first-degree relative without AD, paternal 
longevity, and the presence of an APOE Ɛ4 allele and with a high school/GED or less education by 
maternal longevity and paternal longevity across various ages. AD = Alzheimer’s Disease.  
Cardiovascular Risk Factors With Family History and Alzheimer’s Disease  
Tetrachoric correlation matrices were conducted to examine the associations 
between variables. Those variables that correlated above the r= 0.60 were collapsed with 
others based on the above criterion and their biological relationship (e.g., similar 
condition). Thus, atrial fibrillation and other dysrhythmias were collapsed, as was 
cholesterol/triglycerides and atherosclerosis. Afib/dysrhythmias remained highly 




tested separately in the model. Appendix D presents the output of the tetrachoric 
correlation matrices. Random forest analyses were conducted separately for each 
variable. In females, hypothyroidism, afib/dysrhythmias, CHF, HTN, and chol/athero 
resulted in the greatest decrease in the mean Gini (Gini importance is a metric of 
decreasing misclassification of the outcome variable, with smaller values indicating 
better classification accuracy; Menze et al., 2009; see Appendix D). In males, 
afib/dysrhythmias, hypothyroidism, CHF, MI, and HTN reduced the mean Gini (see 
Appendix D). Using the LASSO regression procedure with a cross-validated Lambda 
(Lambda value corresponding to the minimum mean-squared error; Tibshirani, 1996) 
found CHF, CVA, DM, obesity, hypothyroidism, and afib/dysrhythmias most predictive 
of the outcome variable for both females and males (see Appendix D). The random forest 
and Lasso regression outcomes were used in tandem to select the above-mentioned 
vascular variables for the binary logistic regression models for each sex.  
Examination of Cardiovascular Risk Factors With Family History and Alzheimer’s 
Disease Among Female Probands  
Among females, those with AD (vs. non-case) were more likely to have a history 
of a CVA (15.7% vs. and 8%), obesity (2.6% compared to 0%), hypothyroidism (22.2% 
vs. 0%), afib/dysrhythmias (22.4% compared to 0%), CHF (15.7% vs. 2.8%), but less 
likely to have chol/athero (37.6% compared to 44.1%). Table 14 presents the predictor 







Predictor Variables for Cardiovascular Risk Factors and Family History of Alzheimer’s 
Disease and Cognitive Outcomes in Female Probands 
Characteristic 
Non-Case 
(n = 1707) 
 Alzheimer’s Disease 
(n = 567) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   76.19 7.33    79.68 7.30  -13.47** 
            
Education          0.18  
High School or Less 974 57.3    330 58.2     
Greater than High School 733 42.9    237 41.8     
            
APOE Ɛ4 Status          125.48**  
APOE Ɛ4 Present 446 26.1    293 51.7     
APOE Ɛ4 Absent 1261 73.9    274 48.3     
            
Direct Maternal Lineage of 
ADa 
         4.69*  
Positive Maternal History  179 10.5    79 13.9     
Negative Maternal 
History  
1528 89.5    488 79     
            
Direct Paternal Lineage of 
ADa 
         3.24  
Positive Paternal History  82 4.8    39 6.9     
Negative Paternal History  1625 95.2    528 93.1     
            
Stroke          27.66**  
Yes  136 8    89 15.7     
 None 1571 92    478 84.3     
            
Diabetes Mellitus           2.47  
Yes  307 18    85 15     
None 1400 82    482 85     
            
Hypertension           2.24  
Yes  1055 61.8    371 65.4     
None 652 38.2    196 34.6     
            
Cholesterol/Triglycerides/ 
Atherosclerosis  
         7.07*  
Yes  752 44.1    213 37.6     
None 955 55.9    254 62.4     
            
Obesity           41.51**  
Yes  0 0    15 2.6     
None 1707 100    552 97.4     
            
Hypothyroidism           397.35**  
Yes  0 0    126 22.2     
None 1707 100    441 77.8     
            
Myocardial infarction           0.02  
Yes  211 12.4    68 12     
None 1496 87.6    499 88     






(n = 1707) 
 Alzheimer’s Disease 
(n = 567) 
  
n % M SD  n % M SD X2 t 
            
Atrial Fibrillation and Other 
Dysrhythmias  
         
400.72* 
 
Yes  0 0 
   
127 22.4 
    
None 1707 100 
   
440 77.6 
    
 
           
Congestive Heart Failure  
         
259.45** 
 
Yes  47 2.8 
   
137 15.7 
    
None  1660 97.2 
   
430 75.8 
    
Note. N = 2274. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Parents, siblings, offspring 





Among females, there was an interaction between CHF and paternal lineage of 
AD such that those with both attributes were at a 2-fold increase in the odds of 
developing AD, OR= 2.26, p =.013, compared to those females with neither attribute. See 
Figure 7 for a probability plot for females with a history of CHF and a direct paternal 
linage of AD.  
Figure 7 
 
Females With Direct Paternal Lineage of Alzheimer’s Disease and Congestive Heart 
Failure With Risk for Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for female probands without the presence of an APOE Ɛ4 
allele, MI, CVA, direct maternal lineage of AD, and with a high school/GED or less education by a history 
of CHF and direct paternal lineage of AD across various ages. AD = Alzheimer’s Disease; CHF = 




Among the other vascular variables examined, females with a history of MI had a 
40% lower-odds of developing AD, OR=0.60, 95% CI [.42-0.84], p= .004, than those 
without a history of MI (see Figure 8), while those with a history of a CVA were at a 
two-fold greater risk of developing AD, OR= 2.11, 95% CI [1.50-2.96], p= <.001 (see 
Figure 9). The above results were obtained in models controlling for age at baseline, 
presence of an APOE Ɛ4 allele, and education. P-values for the predictor variables ranged 
from p=<.001 to .564 (see Table 15). Note that a trend level-interaction existed between 
paternal lineage of AD and chol/athero such that those who had both attributes had a 2.69 
greater odds of developing AD, OR= 2.69, p=.076. The interactions between the 
additional cardiovascular risk factors risk factors and family history variables were non-
significant (each individual p >.192; refer to Appendix E; Table E.1). 
Table 15 
 
Female: Binary Logistic Regression With Cardiovascular Risk Factors and Family 
History of Alzheimer’s Disease 
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept -9.27 0.64 -14.4 1 <.001** <0.001 <0.001 <0.001 
Congestive Heart Failure 2.44 0.20 11.97 1 <.001** 11.15 7.76 11.72 
Myocardial Infarction  -0.51 0.18 -2.87 1 .004* 0.60 0.42 0.84 
Cerebrovascular Accident 0.74 0.17 4.31 1 <.001** 2.11 1.50 2.96 
Direct Maternal Lineage of AD 0.45 0.17 2.69 1 .007* 1.57 1.12 2.17 
Direct Paternal Lineage of AD 0.53 0.23 2.26 1 .024* 1.69 1.06 2.67 
APOE Ɛ4 Status 1.34 0.12 11.63 1 <.001** 3.85 3.07 4.84 
Education, High School 
Education or Less 
0.07 0.11 0.58 1 .564 1.07 0.85 1.33 
Age, Years 0.09 0.01 11.89 1 <.001** 1.10 1.08 1.12 
Direct Paternal Lineage of AD × 
Congestive Heart Failure  
-2.10 0.83 -2.50 1 .013* 0.12 0.02 0.71 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious. 
AD = Alzheimer’s Disease; APOE = Apolipoprotein. 






Myocardial Infarction in Females and Risk for Alzheimer’s Disease  
 
Note. This figure presents the probability of AD for females without the presence of an APOE Ɛ4 allele, 
CHF, CVA, and direct lineage of maternal and paternal of AD and with a high school/GED or less 







Cerebrovascular Accident in Females and Risk for Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for female probands with a history of CVA (vs. none) by 
risk for AD across various ages. This is for female probands without the presence of an APOE Ɛ4 allele, 
MI, CHF, and direct maternal and paternal lineage of AD with a high school education/GED/ or less. AD = 
Alzheimer’s Disease.  
Cardiovascular Risk Factors With Family History and Alzheimer’s Disease Among 
Male Probands 
Compared to males without AD, those with AD were more likely to have a 
history of HTN (57.9% compared to 48.9%), obesity (1% compared to 0%), 
hypothyroidism (14% compared to 0%), afib/dysthymias (31.4% compared to 0%), and 
CHF (20.7% compared to 0%). Table 16 presents the predictor variables for males with 






Predictor Variables for Cardiovascular Risk Factors and Family History of Alzheimer’s 
Disease and Cognitive Outcomes in Male Probands  
Characteristic 
Non-Case 
(n = 1314) 
 Alzheimer’s Disease 
(n = 299) 
  
n % M SD  n % M SD X2 t 
            
Age at baseline   74.29 6.55    77.94 7.31  -7.94** 
            
Education          1.47  
High School or Less 575 43.8    143 47.8     
Greater than High School 739 56.2    156 52.2     
            
APOE Ɛ4 Status          71.79**  
APOE Ɛ4 Present  348 26.5    155 51.8     
APOE Ɛ4 Absent 966 73.5    144 48.2     
            
Direct Maternal Lineage of 
ADa 
         0.81  
Positive Maternal History  157 11.9    42 14     
Negative Maternal 
History  
1157 88.1    257 86     
            
Direct Paternal Lineage of 
ADa 
         0.46  
Positive Paternal History  76 5.8    21 7     
Negative Paternal History  1238 94.2    278 93     
            
Stroke          16.58**  
Yes  104 7.9    47 15.7     
None 1210 92.1    252 84.3     
            
Diabetes Mellitus           2.7  
Yes  262 19.9    73 24.4     
None 1052 80.1    226 75.6     
            
Hypertension           7.41*  
Yes  643 48.9    173 57.9     
None 671 51.1    126 42.1     
            
Cholesterol/ Triglycerides/ 
Atherosclerosis 
         5.71*  
Yes  501 38.1    137 45.8     
None 813 61.9    162 54.2     
            
Obesity           8.36*  
Yes  —b — b    3 1     
None 1314 100    296 99     
            
Hypothyroidism           184.01**  
Yes  0 0    42 14     
None 1314 100    257 86     
            
Myocardial infarction           0.01  
Yes  298 22.7    69 23.1     
None 1016 77.3    230 76.9     
            
Atrial Fibrillation and Other 








(n = 1314) 
 Alzheimer’s Disease 
(n = 299) 
  
n % M SD  n % M SD X2 t 
            
Dysrhythmias  
Yes  0 0 
   
94 31.4 
    
None 1314 100 
   
205 68.6 
    
 
           
Congestive Heart Failure  
         
162.53** 
 
Yes  26 2 
   
62 20.7 
    
None  1288 98 
   
237 79.3 
    
Note. N = 1613. AD = Alzheimer’s Disease; APOE = Apolipoprotein. 
a Direct Lineage is parents, grandparents and great grandparents extending back three generations 





Unlike females, there were no interactions between vascular variables and 
parental family history. Individual vascular factors were associated with increased risk 
for AD. Specifically, males with CHF had 11 times greater odds of developing AD, 
OR=11.10, 95% CI [7.31-20.42], p=<.001, those with a history of a CVA were 74% more 
likely to develop AD, OR= 1.74, 95% CI [1.11-2.61], p=.013, those with a history of 
HTN (vs. none) 37% more likely to develop AD, OR= 1.37, 95% CI [1.02-1.84], p=.035, 
and those with a history of high chol/athero were at 48% more likely to develop AD, 
OR= 1.48, 95% CI [1.10-2.01], p=.011, compared to those lacking the risk factor. These 
results were obtained when controlling maternal family history, paternal family history, 
presence of an APOE Ɛ4 allele, age at baseline, and education. P values for the predictor 
variables ranged from p= <.001 to .660 (see Table 17). Figures 10-13 present the 
probability plots for each of the main effects above for male probands across various 
ages. While only main effects were significant for each of the vascular variables, there 
was a trend level interaction between CVA and direct maternal lineage of AD (p 
interaction = 0.069). Specifically, having a history of CVA and maternal lineage of AD 
was associated with a 34% reduced odds of AD, OR= 0.66 (see Appendix F for Table F.1 
and Figure F.1). Appendix E; Table E.2 presents the other non-significant interactions 






Male: Binary Logistic Regression With Cardiovascular Risk Factors and Family History 
of Alzheimer’s Disease  
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept -9.64 0.90 -10.68 1 <.001** <0.001 <0.001 <0.001 
Congestive Heart Failure 2.38 0.26 9.08 1 <.001** 11.10 6.51 11.83 
Cerebrovascular Accident 0.54 0.22 2.48 1 .013* 1.74 1.11 2.61 
Hypertension  0.32 0.15 2.10 1 .035* 1.37 1.02 1.84 
Cholesterol/Triglycerides/ 
Atherosclerosis 
0.39 0.15 2.55 1 .011* 1.48 1.10 2.01 
APOE Ɛ4 Status 1.28 0.15 8.59 1 <.001** 3.61 2.70 4.84 
Direct Maternal Lineage of AD 0.15 0.21 0.69 1 .492 1.15 0.76 1.74 
Direct Paternal Lineage of AD 0.29 0.28 1.03 1 .303 1.33 0.75 2.27 
Education, High School 
Education or Less 
0.06 0.15 0.44 1 .660 1.07 0.80 1.43 
Age, Years 0.09 0.01 8.47 1 <.001** 1.10 1.08 1.12 
         
Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious. 
AD = Alzheimer’s Disease; APOE = Apolipoprotein. 






Congestive Heart Failure in Males and Risk for Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CVA, 
HTN, chol/athero, and direct lineage of maternal and paternal of AD and with a high school/GED or less 
education by history of myocardial infarction (vs. none). AD = Alzheimer’s Disease; CHF = Congestive 






Males With a History of Cerebrovascular Accident and Risk for Alzheimer’s Disease  
 
Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CHF, 
HTN, chol/athero, and direct lineage of maternal and paternal of AD and with a high school/GED or less 






Hypertension in Males and Risk for Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CVA, 
CHF, chol/athero, and direct lineage of maternal and paternal of AD and with a high school/GED or less 






Males With a History of Cholesterol/Triglycerides/Atherosclerosis and Risk for 
Alzheimer’s Disease 
 
Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CVA, 
CHF, HTN, and direct lineage of maternal and paternal of AD and with a high school/GED or less 
education by history of myocardial infarction (vs. none). AD= Alzheimer’s Disease; Chol/Tri/Athero = 
Cholesterol/Triglycerides/Atherosclerosis.  







Overall Summary of the Findings for Females and Males 
 Female Male 
   
First Degree Relative with AD ⇧ 66% (p = <.001; OR=1.66) ⇧ 58% (p=.003; OR=1.58) 
   
Direct Maternal Lineage of AD ⇧ 56% (p= .005; OR= 1.58) Not Significant  
   
Direct Paternal Lineage of AD  Not Significant  Not Significant  
   
Both Parental Lineage of AD  Not Significant  ⇩ 51.3% (p=.054; OR=0.487) 
   
Maternal Longevity Not Significant  ⇧ 54% (p=.041; OR= 1.54) 
   
Paternal Longevity  Not Significant  ⇧ 32% (p=.041; OR= 1.32) 
   
Parental Longevity  Not Significant  ⇧ 11% (p =.041; OR= 0.89) 
   
Maternal Longevity and APOE Allele Not Significant  ⇧ 3.15-fold (p=.020; OR= 3.15) 
   
CHF and Direct Paternal Lineage of AD ⇧ 2.26-fold (p=.013; OR=2.26) Not Significant  
   
Congestive Heart Failure ⇧ 11.15-fold (p=<.001; OR=11.15) ⇧ 11.10-fold (p=<.001; OR=11.10) 
   
Myocardial Infarction  ⇩ 40% (p =.004; OR=0.60) Not Significant  
   
Hypertension  Not Significant  ⇧ 37% (p= .035; OR= 1.37) 
   
Cholesterol/Triglycerides/Atherosclerosis Not Significant  ⇧ 48% (p= .011; OR= 1.48) 
   
Cerebrovascular Accident ⇧ 2.11-fold (p= <.001; OR= 2.11) ⇧ 74% (p= .013; OR= 1.74) 
   








In this population-based sample of 3677 individuals, familial characteristics were 
associated with risk of AD, though some associations varied by sex. In both females and 
males, having a first-degree relative with AD was associated with a 66% (females) and 
58% (males) increase in the odds of developing AD compared to individuals lacking a 
family history of AD. The risk of AD across the older age span varied by sex in that AD 
risk among females declined at extreme ages (e.g., age 106) whereas in males, the risk 
continued to increase well into the 100’s. In females, a direct maternal lineage of AD was 
associated with a 56% increase in the odds of developing AD. Males having both a direct 
maternal and paternal lineage of AD were at a 51.3% reduced odds at a trend level 
significance compared to those with neither parental lineages. Variations by sex were 
also found in the association of exceptional maternal and paternal longevity in risk for 
AD, with females having no significant association with either parental exceptional 
longevity. However, at a trend-level, females with a longer-lived father who also had an 
APOE Ɛ4 allele had a 4.59-fold increase in the odds of developing AD compared to those 
females without. Males with an APOE Ɛ4 allele who also had a longer-lived mother had 
3.15 times the odds of developing AD compared to males lacking each risk factor. In 
contrast, males with a longer-lived mother and longer-lived father had a 11% reduced 
odds of developing AD. Cardiovascular risk factors as main effects were found to be 
associated with risk of developing AD for both male and females, though differed slightly 
with regards to particular cardiovascular risk factors/conditions in the magnitude of 




factors, females with a direct paternal lineage of AD and a history of congestive heart 
failure were at a 2.26-fold increased risk in the odds compared to those females without 
either risk factor. Vascular factors including, CVA and CHF were associated with higher 
odds of developing AD in both females and males, whereas a history of HTN and 
chol/athero were associated with increased risk of AD in males only.  
Previous research has established an association between family history of all-
cause dementia and risk for AD. Van Duijn and colleagues (1991) found in a re-analysis 
of 7 case control studies a 3.5-fold greater risk of developing AD when having a first-
degree relative with all cause dementia, with greater risk associated with having two first-
degree relatives with all cause dementia (7-fold). Fratiglioni and colleagues (1993) also 
found having a first-degree relative with all-cause is associated with a 3.2-fold increased 
risk for AD. Research has also found an association with having a first-degree relative 
with AD and increased risk in the proband. Cannon-Albright and colleagues (2019) found 
having one first-degree relative with AD doubled the risk of developing AD in the 
proband. The risk further doubled when having two first-degree relatives with AD and 
increased to 14 times greater when having four first-degree relatives. The current study is 
consistent with prior work, though the effects were several magnitudes lower in strength. 
Not examined in the current study were numbers of first-degree relatives affected.  
Unlike prior work, however, the current study did not find an association between 
second-and-third degree family history of AD and risk of AD in either males or females. 
Cannon-Alright and colleagues (2019) used cause of death codes on death certificates for 
270,818 individuals in the state of Utah to examine the association between the 




having a second-degree relative in addition to a first-degree relative with AD increased 
the risk two-fold and having an affected third-degree relative increased the risk of 
developing AD by 43%. Here, we found no associations of AD risk (either increased or 
decreased) for those with second-or third-degree relatives. The discrepant results are 
likely associated with differences in methodology, in that the current project relied 
primarily on self-report family history, supplemented death certificate AD diagnosis and 
Medicare claims diagnosis of AD in the proband, as well as variation in the samples (e.g., 
statewide vs. a single county).  
Existing research has also found a link between maternal and paternal 
transmission of AD and risk for AD in the proband. In the Cannon-Albright study (2019), 
there was a link between maternal but not paternal family history of AD and increased 
risk of AD (56%) in the proband. Differences have also been reported in prior work with 
AD risk or AD related biomarkers for maternal and paternal family history of AD (Honea 
et al., 2012; Mosconi et al., 2007; Mosconi et al., 2010). In a cross-sectional study using 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data, Honea and colleagues 
found that regardless of the cognitive status of the individual, a maternal family history of 
AD was associated with increased uptake of Pittsburgh B Compound (PiB; a radiotracer 
marks the deposition of amyloid-beta (Aβ) in the brain, a common biomarker of AD) in 
the parietal and sensorimotor cortices and the precuneus (Honea et al., 2012). Mosconi 
and colleagues (2007) found in a cross-sectional study that having a maternal family 
history of AD was associated with reduced cerebrospinal fluid (CSF) Aβ and increased 
tau/Aβ ratios compared to those participants with a paternal family history or no family 




reduced brain glucose metabolism in the medial-temporal lobe, parietotemporal lobe, 
posterior cingulate, and frontal cortices compared to those participants without a family 
history of the disorder (Mosconi et al., 2007). In a follow-up study, Mosconi and 
colleagues (2010) found that those individuals with a maternal family history of AD who 
were otherwise cognitively normal at baseline had progressive reductions in brain 
glucose metabolism over a two-year period when compared to those with a negative 
family history or a paternal family history of AD. In contrast to the above studies, 
Ehrenkrantz and colleagues (1999) found no evidence of maternal transmission of AD 
but did find evidence of paternal transmission. While the underlying mechanism 
associated with maternal and paternal history of AD and risk remains unclear, hypotheses 
have implicated the role of mitochondrial DNA (Mosconi et al., 2010). Mitochondrial 
DNA is typically passed down through the maternal lineage, though reports have found 
biparental transmission (Luo et al., 2018). Mitochondria are associated with cell 
metabolism and are cellular organelles that provide energy for cellular processes 
(Wallace, 2005). Certain mitochondrial genotypes may be associated with reductions in 
brain glucose metabolism or dysfunctional glucose utilization and thus serve as risk 
factors for AD (Castro et al., 2018). Indeed, brain glucose metabolism is reduced in AD 
(Mosconi et al., 2010) and dysfunction of mitochondrial chaperones (supportive 
structures that maintain homeostasis by shuttling, refolding, and coordinating the 
proteolytic system, thereby reducing the number of misfolded proteins) also occurs in AD 
(Castro et al., 2018). Alternatively, lifestyle factors (e.g., diet, exercise, etc.) could be a 
shared mechanism of familial transmission of AD as familial traditions are often passed 




relationship between direct maternal lineage and increased risk of AD in female 
probands. Notably, the current study found that in males, having both a paternal and 
maternal lineage of AD was associated with reduced risk. A potential explanation may 
include the effects of the competing risk of mortality with age for those with AD in both 
maternal and paternal lineages. Further research is needed to examine mechanisms of AD 
risk with parental lineages.  
The current study found differential risk of AD across the extreme age spectrum 
for males and females. Prior work in the Cache County cohort reported a reduction in risk 
at extreme ages. Miech and colleagues (2002) reported that both incidence of dementia 
and AD exponentially increased until about ages 85 to 90, with decline in males at about 
age 93 and a decline at age 97 for females. This relationship was modified by the 
presence of an APOE Ɛ4 allele (Miech et al., 2002). We extended this work by adding an 
additional 9 years of surveillance for AD. Additionally, methodological differences are 
notable, in that the current work examined associations of AD obtained throughout the 
study, whereas the previous analyses relied only on newly diagnosed cases in the 2nd 
wave of the study. The relationship between longer-lived individuals and a reduction in 
AD risk may relate to compression of morbidity (lower risk of health conditions). 
Consistent with this notion is the finding in the current study that the decline in AD risk 
in late life was no longer evident when including cardiovascular risk factors in statistical 
models.  
Longevity has been related to several social/environmental (e.g., diet and 
exercise) and genetic factors (Sebastiani et al., 2012). A prior study of 424 community-




years of age had a 43% reduction in risk of developing AD compared to those with 
parents living fewer years (Lipton et al., 2010). Andersen and colleagues (2012) found a 
delayed onset of at least one age related disease (cardiovascular disease, obstructive 
pulmonary disease, dementia, diabetes, and stroke) in those with exceptional longevity 
(aged 87 and older) compared to controls. Centenarians were observed to have a reduced 
risk for cancer (91%), hypertension (85%), and dementia (64%) (Andersen et al., 2012). 
Delay of onset of additional conditions and further reductions in the hazards were seen in 
supercentenarians (102-112), suggesting that increasing age was associated with greater 
reductions in morbidity (Andersen et al., 2012). Westendorp and colleagues (2009) 
examined risk of morbidity among familial nonagenarians (two siblings aged 90 and 
above), and sporadic nonagenarians (one individual aged 90 and above) and found 
reduced prevalence rates of MI, DM, HTN, and the use of cardiovascular medication. 
While reductions in morbidity have been found in longer-lived individuals, the presence 
of a genetic risk factor such as APOE may modify the associations between parental 
longevity and AD risk. The relationship between parental and offspring longevity is 
complex and likely reflects the influence of multiple factors including the environment, 
social/cultural practices, and genetics. Human twin studies have found that genetics 
explained 20-30% of the variance in those individuals who survived to age 85 and above 
(Herskind et al., 1996). Prior work has also shown extreme clustering of exceptional 
longevity within some rare families (Alpert et al., 1998; Perls et al., 2000). Sebastiani and 
colleagues (2012) found that 281 single nucleotide polymorphisms (SNPs; including 
those associated with APOE) discriminated between controls and cases of exceptional 




(median of 100). The authors note that exceptional longevity is unlikely to be associated 
with a single or a few genetic components, but rather genetic clusters (Sebastini et al., 
2012). They also recognized that lifestyle and other environmental factors contribute to 
increased survival rates. The findings in the current study only found a relationship 
between maternal and paternal longevity and risk of AD in males. The Cache County 
cohort had greater longevity than the general population at the time (Breitner et al., 
1999). Lack of variance or homogeneity in lifestyle and other genetic factors may have 
diminished the associations between longevity and reduced morbidity that were found in 
other samples. Further research is needed to elucidate this relationship.  
Previous literature has reported on sex differences with regards to risk of AD and 
APOE Ɛ4 status in that, males with one APOE Ɛ4 allele exhibit little-to-no risk of AD 
compared to male non-carriers (Bretsky et al., 1999), and those with two APOE Ɛ4 alleles 
exhibit a 5-fold increase in risk (Payami et al., 1996). Among females, studies have found 
a four-fold increased risk of developing AD when carrying an APOE Ɛ4 allele regardless 
of having one or two Ɛ4 alleles. A prior study found, in a sample of 5,000 deceased and 
autopsied individuals between the ages 25-96, middle-aged females carrying the APOE 
Ɛ4 allele had more brain regions affected by AD pathology than male carriers of the 
APOE Ɛ4 allele (Corder et al., 2004). The current study found an interaction in males 
with parental longevity. Male APOE Ɛ4 carriers with a longer-lived mother showed a 
greater risk for AD. A trend was found in females with an APOE Ɛ4 allele and a longer-
lived father being at greater risk for AD. These results may represent increased risk 





Sex differences are also known to exist in cardiovascular conditions, some as a 
result of differences in gene expression from sex chromosomes (Garcia et al., 2016). 
Existing research has also found an association between cardiovascular risk factors and 
risk for AD (Barnes & Yaffe, 2011; Lennon et al., 2019). Prevalence and incidence rates 
of cardiovascular conditions differ between the sexes, with females being more likely to 
develop DM, strokes, and HTN after age 65 and males developing those conditions 
earlier in life (Mosca et al., 2011). Additionally, females have a greater mortality rate 
following strokes and coronary heart disease as well as increased morbidity at later ages 
(Bots et al., 2017). Research has also found variance in the clinical features of 
cardiovascular disease compared to males, with females expressing differences in the 
symptoms of cardiovascular diseases such as MI (Mosca et al., 2011). Additionally, 
estrogen has been found to be cardioprotective. Females after menopause are at greater 
risk for CVD, high low-density lipoprotein (LDL) cholesterol levels, hypertension, 
diabetes, and obesity (Rodgers et al., 2019). This suggests that sex-differences in 
cardiovascular risk factors may be influenced by changes in hormones. Additional 
research is needed to examine the underlying mechanisms associated with estrogen’s role 
in cardiovascular conditions and risk for AD in women.  
The current study found sex differences in the magnitude of effect for 
cardiovascular predictor variables and AD. Females had double the risk with having a 
history of a CVA, whereas males had a 74% increase in risk. Males and females had an 
11-fold greater risk of AD with a history of CHF however, females had a two-fold 




risk for AD with a history of HTN (37%), and for high cholesterol or atherosclerosis 
being at a 2.69 increased risk for AD at a trend level significance.  
Prior work has examined the association between vascular risk factors and 
conditions and AD in the Cache County cohort (Hayden et al., 2006). Hayden and 
colleagues (2006) found that obesity doubled the risk for females in the hazards of 
developing AD, but not in males. They also found other cardiovascular risk factors were 
associated with risk for vascular dementia (VaD) and this association also differed by 
sex. The current study extends previous work by adding additional years of AD 
surveillance and supplementing data on cardiovascular risk factors from Medicare claims.  
Cardiovascular risk factors such as HTN, hypercholesteremia, and DM have been 
associated with risk for AD (e.g., Lennon et al., 2019), particularly with onsets in mid-life 
(Barnes & Yaffe, 2011). Honig and colleagues (2003) found a history of stroke was 
associated with a 60% increase in the hazards for AD. Cholesterol has also been found to 
be associated with AD and the APOE Ɛ4 allele (Sjögren & Blennow, 2005). Lennon and 
colleagues (2019) in a systematic review found that systolic hypertension was associated 
with a 25% increased risk. Additionally, a meta-analysis by Barnes and Yaffe (2011) 
found that conditions occurring in mid-life (i.e., hypertension, obesity, and DM) 
contributed to a significant portion of cases of AD. CHF in the current study, was among 
the greatest risk factor for AD. CHF has been associated with cognitive decline 
independently of AD and the structures affected by CHF significantly overlap with those 
found to be affected by AD (e.g., hippocampus, precuneus, orbitofrontal cortex, etc.; 




factor (e.g., hypoxia and reduced cerebral blood flow to the inferior mesial temporal lobe 
structures) rather than a condition that drives AD pathology.  
The current study did not examine the use of pharmacological interventions for 
treatment of CHF and the other cardiovascular conditions. Treatments for CHF include 
diuretics, antihypertensives, and beta-blockers (American Heart Association [AHA], 
2015). One common medication for the treatment of CHF is angiotensin-converting 
enzyme (ACE) inhibitors (AHA, 2015), which previous literature has found to be 
associated with reduced risk for AD (Soto et al., 2013). Similarly, within the Cache 
County sample previous research has found a 30% and 31% reduced risk associated with 
thiazide and potassium-sparing diuretics, respectively (Chuang et al., 2014). Conversely, 
the use of medications such as beta-blockers has been associated with an increased risk of 
dementia in older adults (Fares, 2012). Zandi and colleauges (2005) examined the use of 
statins, and risk within the Cache County population and found that statin use at baseline 
was not significantly associated with risk for dementia or AD nor was it associated with 
progression to AD. Previous research suggests that various medications used to treat CHF 
and other cardiac conditions may have varying effects on the overall risk of AD related to 
the cardiac condition. Future research is needed to examine how various types of 
pharmacological interventions for the cardiac conditions may modify their associations 
with AD. The current study was also limited in its ability to examine the underlying cause 
of CHF as well as various classes of CHF, which are associated with differences in 
functional abilities and outcomes (AHA, 2015). There may be a specific underlying 





In general, the risk for cardiovascular conditions increases with age and is 
associated greater risk of mortality (Virani et al., 2020). Future research is needed to 
examine the competing risk of mortality versus AD and its association with 
cardiovascular risk factors/conditions. Cardiovascular conditions are also associated with 
reduced longevity (Virani et al., 2020), and thus those with parental family history of 
cardiovascular conditions may have greater cardiovascular load and shorter survival time. 
The current findings with cardiovascular risk factors/conditions and reduced risk and the 
limited associations with family history may be related to the competing risk of mortality 
and the survival time of the proband.  
Significant overlap also exists between vascular dementia (VaD) and AD, which 
increases with advanced age (Strub, 2003). Both disorders are associated with the 
presence of cardiovascular conditions (Strub, 2003), though condition differ in their 
pathophysiological mechanisms. The current study was restricted in examining AD and 
did not examine the association with VaD. The presence of both VaD and AD, may have 
different associations with cardiovascular risk factors and conditions. Future research 
should examine the relationship between cardiovascular risk factors/conditions and 
family history with risk of VaD in the proband.   
A trend-level association was found in the current study in males with a history of 
CVA and a direct maternal lineage of AD being at 34% reduced risk for AD. This finding 




Study Strengths and Limitations  
The current study had a number of strengths. The base Cache County Study was a 
large community-based sample with 90% enrollment of the base population. Thus, 
generalizability to other community-dwelling individuals is likely greater than studies 
relying on samples from other settings, such as clinical sites or medical centers. The 
follow-up extending up to 12 years is an additional strength. Furthermore, the rich dataset 
was supplemented up to an additional seven years through the addition of Medicare 
Claims and death certificate data via linkage with the UPDB. This linkage provided 
greater surveillance of both AD (additional 209 cases of AD) and cardiovascular risk 
factors and condition beyond the end of data collection. Additionally, UPDB linkage was 
critical in providing data on extensive familial genealogy extending back four 
generations. Nonetheless, data from Medicare claims and death certificates are limited. 
Death certificates have been known to underestimate the prevalence of AD, as the 
certifying physician may be unaware of an AD condition (Frecker et al.,1995; Raiford et 
al., 1994). Alternatively, certifying physicians may assume an AD diagnosis for a 
different form of dementia. For example, disorders that mimic the clinical symptoms of 
AD such as limbic-predominant age-related TDP-43 encephalopathy (LATE) (Robinson 
et al., 2020) and argyrophilic grain disease (Tolnay & Clavaguera, 2004). Medicare 
claims data, which are used for billing purposes, are not a direct substitute for clinical 
diagnoses (American Medical Association [AMA], 2014). To reduce misclassification for 
AD from claims data, the current study required the occurrence of a minimum of two 
ICD-9 AD claims within 18 months. This criterion is highly correlated with autopsy 




conditions, the age of onset inferred from Medicare claims data may post-date the actual 
onsets as individuals are eligible for Medicare at age 65 (AMA, 2014). Many of the 
chronic health conditions such as hypertension and hypothyroidism occur frequently in 
mid-life (Fryar et al., 2017), and thus some conditions were not considered risk factors if 
the inferred age of onset postdated the onset of AD. Despite the limitations with 
Medicare claims and death certificates they were used to augment Cache County Study 
data and the majority of the AD designations and risk factors were obtained from the 
Cache County Study directly, mitigating these concerns. While the Cache County cohort 
may be broadly generalizable as community-dwelling individuals, participants were 
primarily white, of Northern European descent, and relatively highly educated. Thus, 
study results may not generalize to other populations with greater ethnic and cultural 
diversity. Lastly, the rich Cache County Study dataset with linkage to genealogical, state, 
and federal health data allowed for the examination of sex differences, family history of 
AD, familial exceptional longevity, and vascular factors as risk factors for AD within a 
single sample. 
Implications and Future Directions 
There are several implications from the current study. This study highlights the 
importance of ascertaining first-degree relative information about AD for both males and 
females. It may also be beneficial clinically when working with patients to provide sex-
specific interventions/counseling related to modifiable cardiovascular risk factors. 
Heightened surveillance and treatment for males at risk for CHF, CVA, HTN, and 




for CHF and CVA would also benefit from surveillance and primary prevention to reduce 
future risk of AD. This includes changes in diet, improving sleep, increasing physical 
activity, managing menopausal changes, and use of pharmacological interventions such 
as ACE inhibitors, which has been associated with reducing risk for AD (Ju et al., 2013; 
Soto et al., 2013; Tang et al.,1996; Tschanz et al., 2013; Yaffe et al., 2014) and 
improving cardiovascular health (Shay et al., 2015). This study also supports the notion 
of managing cardiovascular health as an area of lowering risk for AD and suggests the 
benefit of providing sex-specific intervention strategies. Additionally, monitoring both 
males and females for specific cardiovascular conditions when a positive first-degree 
family history of AD, may also be an effective prevention strategy.  
There was limited association between direct maternal and paternal lineage of AD 
and cardiovascular risk factors. Future research should continue to assess these risk 
factors and modifying relationships with risk for AD. Not examined in this study was 
family history of vascular risk factors or conditions. A family history of stroke and MI 
has been found to be more predictive of risk for the condition in females compared to 
males (Patel et al., 2007; Touzé & Rothwell, 2007). Specifically, females who had 
experienced a stroke were 15% more likely to have a first-degree relative with a history 
of a stroke than males who had a stroke, and females with a paternal family history of a 
stroke were at a 25% increased risk for a stroke compared to males with a similar family 
history (Touzé & Rothwell, 2007). A study by Patel and colleagues (2007), found an 
association with family history of MI and greater risk in females compared to males. 
These studies suggest sex differences may exist in family history of vascular factors. 




examining family history of AD and vascular factors together may potentially identify 
high risk individuals for both conditions and a group for whom strategies in primary 
prevention may be particularly beneficial. Overall, this study highlights the importance of 
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Appendix C: Direct Maternal and Paternal Lineage Diagram  
Figure C.1 
 




Appendix D: Tetrachoric Correlation Matrix, Random Forest  
Analyses, and Lasso Regression Output 
Table D.1 
 
Tetrachoric Correlation Matrix  
 
 CHF CVA DM MI CHOL HTN AFIB ATHERO OBESE HYPO DYSRHY 
            
CHF 1.00 0.23 0.22 0.28 0.04 0.22 0.61 0.44 0.47 0.40 0.54 
CVA 0.23 1.00 0.20 0.21 0.10 0.26 0.25 0.30 0.19 0.20 0.25 
DM 0.22 0.20 1.00 0.24 0.16 0.34 0.13 0.17 0.36 0.10 0.16 
MI 0.28 0.21 0.24 1.00 0.29 0.17 0.17 0.08 0.21 0.06 0.19 
CHOL 0.04 0.10 0.16 0.29 1.00 0.28 0.09 0.19 0.19 0.18 0.17 
HTN 0.22 0.26 0.34 0.17 0.28 1.00 0.28 0.34 0.41 0.23 0.33 
AFIB 0.61 0.25 0.13 0.17 0.09 0.28 1.00 0.59 0.33 0.68 0.83 
ATHERO 0.44 0.30 0.17 0.08 0.19 0.34 0.59 1.00 0.44 0.61 0.66 
OBESE 0.47 0.19 0.36 0.21 0.19 0.41 0.33 0.44 1.00 0.50 0.50 
HYPO 0.40 0.20 0.10 0.06 0.18 0.23 0.68 0.61 0.50 1.00 0.71 
DYSRHY 0.54 0.25 0.16 0.19 0.17 0.33 0.83 0.66 0.50 0.71 1.00 




Tetrachoric Correlation Matrix With Combined Atrial Fibrillation and Dysthymias 
 CHF CVA DM MI CHOL HTN ATHERO OBESE HYPO RHYTHMIAS 
           
CHF 1.00 0.27 0.17 0.27 0.02 0.25 0.50 0.55 0.49 0.66 
CVA 0.27 1.00 0.13 0.20 0.08 0.23 0.35 0.12 0.26 0.33 
DM 0.17 0.13 1.00 0.24 0.15 0.32 0.18 0.35 0.11 0.17 
MI 0.27 0.20 0.24 1.00 0.25 0.15 0.08 0.24 0.07 0.23 
CHOL 0.02 0.08 0.15 0.25 1.00 0.26 0.19 0.23 0.18 0.14 
HTN 0.25 0.23 0.32 0.15 0.26 1.00 0.34 0.51 0.23 0.33 
ATHERO 0.50 0.35 0.18 0.08 0.19 0.34 1.00 0.51 0.59 0.65 
OBESE 0.55 0.12 0.35 0.24 0.23 0.51 0.51 1.00 0.59 0.62 
HYPO 0.49 0.26 0.11 0.07 0.18 0.23 0.59 0.59 1.00 0.69 
RHYTHMIAS 0.66 0.33 0.17 0.23 0.14 0.33 0.65 0.62 0.69 1.00 







Tetrachoric Correlation Matrix With Collapsed Cholesterol/Atherosclerosis and Atrial 
Fibrillation and Other Dysrhythmias  
 CHF CVA DM MI CHOL/ATHERO HTN OBESE HYPO RHYTHMIAS 
          
CHF 1.00 0.27 0.17 0.26 -0.02 0.28 0.53 0.52 0.67 
CVA 0.27 1.00 0.16 0.26 0.11 0.26 0.16 0.27 0.31 
DM 0.17 0.16 1.00 0.31 0.15 0.33 0.31 0.12 0.13 
MI 0.26 0.26 0.31 1.00 0.17 0.22 0.27 0.13 0.16 
CHOL/ATHERO -0.02 0.11 0.15 0.17 1.00 0.22 0.22 0.14 0.07 
HTN 0.28 0.26 0.33 0.22 0.22 1.00 0.47 0.15 0.32 
OBESE 0.53 0.16 0.31 0.27 0.22 0.47 1.00 0.59 0.59 
HYPO 0.52 0.27 0.12 0.13 0.14 0.15 0.59 1.00 0.71 




Variance Inflation Factors Analysis for Research Question 4  
Variable Variance Inflation Factors 
  
Sex  1.05 
Age  1.19 
Education  1.03 
Ethnicity  1.01 
APOE Ɛ4 Allele  1.07 
Direct Maternal Lineage 1.03 






Obesity  1.00 
Cholesterol/Atherosclerosis  1.12 
Hypothyroidism  1.00 
Atrial Fibrillation and Other Dysrhythmias  1.00 
  




Table D.5  
 
Female: Random Forest Analysis Output for Research Question 4  
Variable Mean Decrease in Gini 
  
Age at Baseline  127.68 
Education  9.63 
Ethnicity  1.83 
APOE Ɛ4 Status  37.47 
Direct Maternal Lineage  7.84 
Direct Paternal Lineage  7.20 
Congestive Heart Failure  50.19 
Cerebrovascular Accident  9.16 
Diabetes Mellitus  8.34 
Myocardial Infarction  7.16 
Hypertension  10.79 
Obesity 5.87 
Cholesterol/Atherosclerosis  10.12 
Hypothyroidism  101.75 





Male: Random Forest Analysis Output for Research Question 4  
Variable Mean Decrease in Gini 
  
Age at Baseline  74.44 
Education  7.86 
Ethnicity  0.94 
APOE Ɛ4 Status  18.79 
Direct Maternal Lineage  4.90 
Direct Paternal Lineage  3.86 
Congestive Heart Failure  29.17 
Cerebrovascular Accident  4.92 
Diabetes Mellitus  5.37 
Myocardial Infarction  6.85 
Hypertension  6.77 
Obesity 0.60 
Cholesterol/Atherosclerosis  6.29 
Hypothyroidism  34.51 









Female: Random Forest Plot for Importance of Variable for Model Prediction  
 
Note. Gender/sex is not predictive as this is a stratified model and males were removed. v1age = Age at 
baseline; predem_hypothy_medclm = hypothyroidism;predem_rhythmias_medclm = Atrial fibrillation and 
other dysrhythmias; predem_chf_ccms_claim = congestive heart failure; apoe4= APOE Ɛ4 status; 
predem_htn_ccms_claim = hypertension; educ2 = education; predem_cva_ccms_claim = cerebrovascular 
accident; predem_dm_ccms_claim = diabetes mellitus; dc_ccms_maternalfamhx = Direct Maternal Lineage 
of AD; dc_ccms_paternalfamhx = direct paternal lineage of AD; predem_mi_ccms_claim = myocardial 






Male: Random Forest Plot for Importance of Variable for Model Prediction  
 
Note. Gender/sex is not predictive as this is a stratified model and females were removed. v1age = Age at 
baseline; predem_hypothy_medclm = hypothyroidism; predem_rhythmias_medclm = Atrial fibrillation and 
other dysrhythmias; predem_chf_ccms_claim = congestive heart failure; apoe4 = APOE Ɛ4 status; 
predem_htn_ccms_claim = hypertension; educ2 = education; predem_cva_ccms_claim = cerebrovascular 
accident; predem_dm_ccms_claim = diabetes mellitus; dc_ccms_maternalfamhx = Direct Maternal Lineage 
of AD; dc_ccms_paternalfamhx = direct paternal lineage of AD; predem_mi_ccms_claim = myocardial 






LASSO Regression Analysis With Lambda Set at 0.09 for Research Question 4 




Age at Baseline 0.01 
Education  — 
APOE Ɛ4 Status  0.00 
Direct Maternal Lineage of AD — 
Direct Paternal Lineage of AD — 
Congestive Heart Failure  0.26 
Cerebrovascular Accident  — 
Diabetes Mellitus  — 
Myocardial Infarction  — 
Hypertension  — 
Obesity  — 
Cholesterol/Atherosclerosis  — 
Hypothyroidism  1.04 





LASSO Regression Analysis With Cross-Validation Lambda  




Age at Baseline -0.09 
Education  — 
APOE Ɛ4 Status  -1.14 
Direct Maternal Lineage of AD -0.04 
Direct Paternal Lineage of AD -0.11 
Congestive Heart Failure  -1.45 
Cerebrovascular Accident  -0.21 
Diabetes Mellitus  0.02 
Myocardial Infarction  0.47 
Hypertension  — 
Obesity  -0.94 
Cholesterol/Atherosclerosis  — 
Hypothyroidism  -4.10 






Appendix E: Male and Female Binary Logistic  
Regression Nonsignificant Interactions 
Table E.1 
 
Female: Binary Logistic Regression Cardiovascular Risk Factors by Direct Maternal 
and Paternal Lineage of Alzheimer’s Disease 
Parameter β SE Wald df Sig. Exp(β) 
       
Congestive Heart Failure × DMLAD 0.54 0.71 0.76 1 .445 1.72 
Cerebrovascular Accident × DMLAD 0.51 0.48 1.05 1 .300 1.66 
Cerebrovascular Accident × DPLAD -0.69 0.73 -0.95 1 .344 0.50 
Diabetes Mellitus × DMLAD -0.50 0.48 -1.05 1 .295 0.60 
Diabetes Mellitus × DPLAD -0.17 0.55 -0.31 1 .760 0.84 
Myocardial Infarction × DMLAD -0.15 0.50 -0.31 1 .760 0.86 
Myocardial Infarction × DPLAD -0.59 0.87 -0.70 1 .500 0.55 
Hypertension × DMLAD 0.20 0.33 0.33 1 .552 1.22 
Hypertension × DPLAD 0.22 0.45 0.45 1 .635 1.24 
Cholesterol/Triglycerides/Atherosclerosis × DMLAD -0.42 0.32 -1.30 1 .192 -0.42 
Cholesterol/Triglycerides/Atherosclerosis × DPLAD 0.79 0.45 1.77 1 .076 2.21 
Hypothyroidism × DMLAD -0.52 871.4 -0.0006 1 .999 0.59 
Hypothyroidism × DPLAD -0.14 1427.0 -0.0001 1 .999 0.87 
Obesity × DMLAD  0.26 821.1 0.0003 1 .997 1.29 
Obesity × DPLAD  NA NA NA — NA NA 
Atrial Fibrillation and Other Dysrhythmias × DMLAD -0.38 906.4 -0.0004 1 .999 0.68 
Atrial Fibrillation and Other Dysrhythmias × DPLAD -0.22 1209 -0.0002 1 .999 0.81 
       
Note. Each cardiovascular risk factor by direct maternal and paternal lineage of AD is from a different 
binary logistic regression. AD = Alzheimer’s Disease; DMLAD = Direct Maternal Lineage of AD; DPLAD 
= Direct Paternal Lineage of AD.  






Male: Binary Logistic Regression Cardiovascular Risk Factors by Direct Maternal and 
Paternal Lineage of Alzheimer’s Disease 
Parameter β SE Wald df Sig. Exp(β) 
       
Congestive Heart Failure × DMLAD -0.22 0.91 -0.25 1 .805 0.80 
Congestive Heart Failure × DPLAD 1.13 1.22 0.93 1 .353 3.11 
Cerebrovascular Accident × DMLAD -1.38 0.76 -1.82 1 .069 0.48 
Cerebrovascular Accident × DPLAD 0.12 0.98 0.12 1 .901 0.12 
Diabetes Mellitus × DMLAD 0.10 0.46 0.21 1 .833 1.10 
Diabetes Mellitus × DPLAD -0.50 0.68 -0.73 1 .463 0.61 
Myocardial Infarction × DMLAD 0.39 0.47 0.83 1 .404 1.48 
Myocardial Infarction × DPLAD 0.56 0.69 0.82 1 .413 1.76 
Hypertension × DMLAD -0.15 0.42 -0.35 1 .725 0.86 
Hypertension × DPLAD 0.78 0.60 1.30 1 .193 2.19 
Cholesterol/Triglycerides/Atherosclerosis × DMLAD 0.05 0.40 0.14 1 .884 1.25 
Cholesterol/Triglycerides/Atherosclerosis × DPLAD 0.23 0.54 0.42 1 .671 1.30 
Hypothyroidism × DMLAD -0.19 983.34 -0.0002 1 .999 0.83 
Hyperthyroidism × DPLAD -0.23 1617.26 -0.0001 1 .999 1.27 
Obesity × DMLAD  NA NA NA — NA NA 
Obesity × DPLAD  0.16 655.67 0.0003 1 .999 1.18 
Atrial Fibrillation and Other Dysrhythmias × DMLAD -0.11 1020.51 -0.0001 1 .999 0.89 
Atrial Fibrillation and Other Dysrhythmias × DPLAD -0.31 1955.38 -0.0002 1 .999 1.37 
       
Note. Each cardiovascular risk factor by direct maternal and paternal lineage of AD is from a different 
binary logistic regression. AD = Alzheimer’s Disease; DMLAD = Direct Maternal Lineage of AD; DPLAD 
= Direct Paternal Lineage of AD.  





Appendix F: Male: Binary Logistic Regression Trend Level Interaction  
for Cerebrovascular Accident and Direct Maternal  
Lineage of Alzheimer’s Disease 
Table F.1 
 
Male: Binary Logistic Regression for Cerebrovascular Accident and Maternal Family 
Lineage of Alzheimer’s Disease 
Parameter b SE Wald df 
 
OR 
OR 95% CI 
Sig. Lower Upper 
         
Intercept -9.77 0.91 -10.76 1 <0.001** <0.001 <0.001 <0.001 
Congestive Heart Failure 2.37 0.26 9.04 1 <0.001** 11.71 6.47 11.82 
Cerebrovascular Accident 0.69 0.23 3.02  0.002* 1.99 1.26 3.09 
Hypertension  0.30 0.15 2.07 1 0.04* 1.36 1.02 1.83 
Cholesterol/Triglycerides/ 
Atherosclerosis 
0.41 0.15 2.63  0.001* 1.50 1.11 2.04 
APOE Ɛ4 Status 1.28 0.15 8.57 1 <0.001** 3.60 2.69 4.84 
Direct Maternal Lineage of AD 0.28 0.22 1.30 1 0.19 1.33 0.86 2.03 
Direct Paternal Lineage of AD 0.30 0.28 1.09 1 0.28 1.35 0.77 2.30 
Education  0.07 0.15 0.45 1 0.65 1.07 0.80 1.43 
Age 0.09 0.01 8.56 1 <0.001** 1.10 1.07 1.12 
Direct Maternal Lineage of AD 
× Cerebrovascular Accident 
-1.38 0.52 -1.82 1 0.07 0.25 0.48 1.01 
         
Note. AD = Alzheimer’s Disease. 








Figure F.1  
 
Males With History of Cerebrovascular Accident and Direct Maternal Lineage and Risk 
for Alzheimer’s Disease 
 
Note. This figure presents a probability plot male probands with a direct maternal lineage of AD by history 
of a cerebrovascular accident (CVA) across various ages for male probands without the presence of an 
APOE Ɛ4 allele, without a history of hypertension or cholesterol/triglycerides/atherosclerosis or congestive 
heart failure and with a high school/GED/or less education. This model was not retained as it was not the 
most parsimonious and did not have the lowest AIC, BIC, and R-squared compared to the model presented 
in cardiovascular risk factors with family history and Alzheimer’s disease among male probands section. 
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Researched neuropsychological batteries and tests to be administered via telehealth.  
 
Graduate Research Assistant (August 2017-August 2018) 
Cache County Family Study, Utah State University, Logan, UT.  
Supervisor: JoAnn Tschanz, Ph.D.  
Created a database in RedCap, assisted in completing IRB protocol, supported the study 
running, collected field interview data, and entered data. 
 
Psychometrician and Research Assistant (May 2012-June 2015) 
Knight Alzheimer Disease Research Center, Washington University in St. Louis 
School of Medicine, St. Louis, MO. 
Supervisor: Dr. Jason Hassenstab, Ph.D. 
Administered neuropsychological batteries to older adults with and without cognitive 
impairment, analyzed collected data, maintained data integrity, and recorded behavioral 
observations.  
 
Research Assistant and Research Coordinator (May 2013- June 2015) 
Roe Lab: R01 Grant-Factors Impacting Driving in Older Adults, Washington 
University in St. Louis School of Medicine, St. Louis, MO. 
Supervisor: Dr. Catherine Roe,  
Conducted navigational assessments, analyzed, and maintained data, insured compliance 
with IRB protocol, collaborated on manuscripts, and worked with an integrated 
disciplinary team.  
 
Research Coordinator (May 2014-June 2015) 
Dominantly Inherited Frontotemporal Dementia Study, Washington University in 
St. Louis School of Medicine, St. Louis, MO.  
Supervisor: Nupur Ghoshal, M.D., Ph.D.  
Maintained protocol compliance, assisted in grant renewal process, coordinated, and 





Research Assistant (May 2014-June 2015) 
Driving Simulator Lab, Washington University in St. Louis School of Medicine, St. 
Louis, MO. 
Supervisor: David Carr, M.D.  
Assisted in grant writing, running participants, conducted data analyses, maintained data 
compliance, and assisted in manuscript writing.  
 
Undergraduate Research Assistant (June 2011-August 2011) 
Perception and Action Lab, Indiana University, Bloomington, IN  
Supervisors: Geoffery Bingham, Ph.D. and Winona Snapp-Childs, Ph.D.  
Administered experiments, assisted in data analyses, and conducted experiments with 




Abnormal Psychology (Summer 2016, Fall 2016, Summer 2017) 
Research Methods (Fall 2015) 
 
Graduate Teaching Assistant  
Intellectual Assessment (Spring 2017) 
Health Psychology (Spring 2017)  
Introductory Psychology (Fall 2015-Spring 2016) 
Scientific Thinking and Research Methods (Fall 2015-Spring 2016) 
 
Awards and Honors  
Utah State University – Gloria Foster George Scholarship (2017 – 2018) 
Utah State University – Annual Kranz Travel Research Award (2015 – Current)  
 
Professional Memberships and Organizations 
2019 to Current American Psychological Association Student Affiliate 
APA Division memberships 
Division 12 Student Membership 
Division 40 Student Membership 
Professional Services  
Ad hoc reviewer for The American Journal of Geriatrics Society.  
 
